WO2009105275A2 - Human biomarkers for determining intrinsic b-cell defects - Google Patents
Human biomarkers for determining intrinsic b-cell defects Download PDFInfo
- Publication number
- WO2009105275A2 WO2009105275A2 PCT/US2009/001131 US2009001131W WO2009105275A2 WO 2009105275 A2 WO2009105275 A2 WO 2009105275A2 US 2009001131 W US2009001131 W US 2009001131W WO 2009105275 A2 WO2009105275 A2 WO 2009105275A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- human subject
- vaccine
- aid
- Prior art date
Links
- 230000007547 defect Effects 0.000 title claims abstract description 37
- 239000000090 biomarker Substances 0.000 title abstract description 15
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 207
- 229960005486 vaccine Drugs 0.000 claims abstract description 38
- 230000028996 humoral immune response Effects 0.000 claims abstract description 24
- 244000052769 pathogen Species 0.000 claims abstract description 6
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 5
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 claims description 89
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 54
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 29
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 238000000338 in vitro Methods 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 20
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 19
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 12
- 108091023040 Transcription factor Proteins 0.000 claims description 11
- 102000040945 Transcription factor Human genes 0.000 claims description 11
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 11
- 108091008875 B cell receptors Proteins 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 5
- 230000037439 somatic mutation Effects 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 12
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 6
- 102000018358 immunoglobulin Human genes 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 229940072221 immunoglobulins Drugs 0.000 abstract description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 37
- 102000004388 Interleukin-4 Human genes 0.000 description 37
- 210000001806 memory b lymphocyte Anatomy 0.000 description 34
- 230000007423 decrease Effects 0.000 description 32
- 210000005259 peripheral blood Anatomy 0.000 description 24
- 239000011886 peripheral blood Substances 0.000 description 24
- 230000032683 aging Effects 0.000 description 23
- 238000002255 vaccination Methods 0.000 description 19
- 210000002829 igm memory b cell Anatomy 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102100027207 CD27 antigen Human genes 0.000 description 13
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 101150013553 CD40 gene Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 10
- 238000011529 RT qPCR Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 102100032937 CD40 ligand Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000003393 splenic effect Effects 0.000 description 6
- 108010029697 CD40 Ligand Proteins 0.000 description 5
- 102100024207 Transcription factor COE1 Human genes 0.000 description 5
- 101710182998 Transcription factor COE1 Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 238000012270 DNA recombination Methods 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- -1 AIOH or AIPO4 Chemical class 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- 108010078072 VDJ Recombinases Proteins 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 208000026640 hyper-IgM syndrome type 3 Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Definitions
- This invention relates to human biomarkers (i.e., E47, AID, IgH that has undergone class switching), which characterize the immune potential of B lymphocytes, which produce immunoglobulins (Ig), and their ability to respond to infections by pathogens and vaccines.
- human biomarkers i.e., E47, AID, IgH that has undergone class switching
- IgH immunoglobulins
- Aging affects the humoral immune response in humans both quantitatively and qualitatively with reduced antibody specificity, affinity, and isotype switch (1-3).
- the changes in the humoral immune response during aging significantly contribute to the increased susceptibility of the elderly to infectious diseases and reduce the protective effects of vaccination.
- the decreased ability of aged subjects to produce high affinity protective antibody responses against infectious agents or experimental antigens likely also results from additional defects in required T-cell signaling to B cells (4-6).
- B-cell function may suffer from lack of a good T-cell help in aging, intrinsic changes in B cells also occur and have a significant impact on antibody production and somatic mutation (3, 7-9).
- B cells can switch the expression of surface Ig from IgM to IgG, IgE, or IgA.
- This DNA recombination takes place between two switch (S) regions, one located immediately upstream (5 1 ) of the ⁇ CH (donor site) and one 5' of one of the other CH regions ( ⁇ , ⁇ or ⁇ ) (acceptor site) to produce IgG, IgE or IgA.
- S switch
- the CSR requires chromatin opening of S regions, recognition and cleavage of the target DNA by an endonuclease and repair and ligation of the cleaved ends (10-15).
- CSR is extremely important for the humoral immune response, because it generates antibodies of the same specificity, but with different effector functions.
- human naive B cells can be activated to undergo CSR with anti-CD40 or CD40L, together with cytokine signals which can direct CSR to distinct classes.
- CD40- CD40L interaction for CSR is provided by the discovery that mutations in either the CD40 or CD40L (CD154) gene cause the hyper IgM (HIGM) syndrome, HIGM3 or HIGM1 , respectively, characterized by very low levels of serum IgG, IgA, and IgE, with normal or elevated IgM, associated with defective germinal center formation (16).
- mice (8, 9) that the E2/ ⁇ -encoded transcription factor E47 is down-regulated in old splenic B cells, leading to a reduction in AID and in CSR.
- the invention provides biomarkers for predicting or determining whether there is an intrinsic defect in the B cells participating in a humoral immune response of a human subject.
- the subject may have reduced immunocompe- tence because of age (e.g., less than 3 or more than 65 years of age), disease or treatment of a disease, a genetic defect, suppression of the immune system, etc.
- age e.g., less than 3 or more than 65 years of age
- disease or treatment of a disease e.g., less than 3 or more than 65 years of age
- a genetic defect e.g., a genetic defect
- suppression of the immune system etc.
- reduction in B-cell expression of a single biomarker may be suffi- cient for predicting or determining whether there is an intrinsic B-cell defect, it could also be required that at least two of the biomarkers or all three (i.e., E47, AID and IgH that has undergone class switching) are reduced.
- a method of the invention may include one or more of the following: obtaining a biological sample, which contains B cells, from a human subject; optionally, isolating B cells from the biological sample (i.e., the method may detect expression from a biological sample that was neither fractionated nor selected for cell subpopulations); optionally, stimulating in vitro B cells to divide and differentiate at least some B cells being cultured (i.e., the method may detect expression in a biological sample or cell subpopulation that was not stimulated or cultured in vitro) or, alternatively, freshly isolated B cells are analyzed ex vivo without being stimulated during in vitro culture; and detecting expression in the B cells of transcription factor E47, activation-induced cytidine deaminase (AID), or an immunoglobulin heavy chain (IgH) that has undergone class switching to IgG, IgE or IgA.
- AID activation-induced cytidine deaminase
- IgH immunoglobulin heavy chain
- proxies for the IgH biomarker may be detected in B cells such as episomes produced by DNA recombination, Ig ⁇ 1 circle transcripts, or somatic mutation. Therefore, only obtaining a biological sample and detecting expression of a biomarker in B cells are required in the method. In some embodiments, antibody production may not be measured.
- a human subject may be or may have been immunized with a vaccine.
- the subject may be a resident in a healthcare or assisted living facility, a reci- pient of a solid organ transplant or renal dialysis, afflicted by a chronic cardiovascular or pulmonary disorder, at risk for or affected by autoimmune disease (e.g., type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, especially those with a significant B-cell component involved in pathogenesis), immunocompromised or immunosuppressed, etc. in need of treatment.
- the subject may be young and needing a series of childhood immunizations. Having an intrinsic B-cell defect in the subject may be used to stage disease or to recommend treatment at an early or late stage of disease pathogenesis.
- Figure 1 shows age-related changes in B-cell percentages and numbers.
- B cells isolated from the peripheral blood (PBMC) of subjects of different ages using CD19 magnetic beads were analyzed for percentage of cells expressing membrane CD19 (Fig. 1A), and absolute number of CD19+ cells calculated (Fig. 1B).
- Fig. 1A percentage of cells expressing membrane CD19
- Fig. 1B absolute number of CD19+ cells calculated
- Fig. 1B the percentages of naive (lgG-/lgA-/ CD27-) B cells, IgM memory (lgG-/lgA-/CD27+) B cells
- switch memory lgG+/lgA+/CD27+
- Na ⁇ ve B-cell and IgM memory B-cell percentages showed significant quadratic relationships to age.
- Significant differences between young and old are indicated by *(p ⁇ 0.05) and * *(p ⁇ 0.01 ).
- the solid line refers to linear regression; the dashed line refers to quadratic regression.
- Figure 2 shows aging decreases class switch in activated peripheral blood-derived human B cells.
- B cells (10 6 cells/ml), isolated from the peripheral blood of subjects of different ages using CD19 magnetic beads, were cultured with anti-CD40 (1 ⁇ g/ml) and IL-4 (10 ng/ml), for a period of 6 to 7 days. At the end of this period, cells were harvested, RNA was extracted, and sqPCR reactions were performed to evaluate CTs and GAPDH transcripts. Undiluted and 1 :4 diluted RT-PCR from five representative subjects are shown in Fig. 2A. Densitometric analyses (arbitrary units) of CTs, normalized to GAPDH, from 46 subjects of different ages are shown in Fig. 2B.
- the numbers shown for each sample are percentages of the highest value (randomly chosen) normalized to 100.
- B cells were cultured as described above. IgG level in culture super- natants were determined by ELISA.
- the IgG levels in serum were determined by ELISA.
- the solid line refers to linear regression; the dashed line refers to quadratic regression.
- Figure 3 shows aging decreases AID mRNA expression in activated peripheral blood-derived human B cells.
- B cells (10 6 cells/ml), isolated from the peripheral blood of subjects of different ages using CD19 magnetic beads, were cultured with anti-CD40 (1 ⁇ g/ml) and IL-4 (10 ng/ml), for a period of 6 to 7 days. At the end of this period, cells were harvested, RNA was extracted, and sqPCR reactions were performed to evaluate AID and GAPDH transcripts.
- the graph in Fig. 3A shows the amounts of AID mRNA, normalized to GAPDH, from 34 subjects of different ages. These are 34 out of the 46 evaluated by sqPCR (not shown).
- Sorted memory (CD19+CD27+) B cells or naive (CD19+CD27-) B cells were stimulated (10 4 cells/200 ⁇ l) with anti- CD40/IL-4, alone or together with F(ab') 2 fragments of goat anti-human Ig, for a period of five days (at later times, viability in culture significantly dropped off).
- the graphs in Figs. 4A, 4B, 4C and 4D show amounts of AID mRNA (qPCR) which are normalized to GAPDH 1 expressed as ⁇ Cts from four pairs of young (white columns) and old (black columns) subjects. For each pair, results are expressed as percentages of the anti-CD40/IL-4-stimulated memory B cells from young subjects taken as 100.
- Ages of young #1 , 2, 3 and 4 were 20, 21 , 24 and 23 years and those of old #1 , 2, 3 and 4 were 72, 82, 74 and 71 years. These subjects are not represented in Fig. 3.
- the differences between anti- CD40/IL-4-stimulated memory B cells from young and old subjects are p ⁇ 0.05 for the four pairs, and between anti-CD40/IL-4/lgM-stimu- lated memory B cells from young and old subjects (columns 2 vs. 6) are p ⁇ 0.01 (pairs #1 and #3), p ⁇ 0.05 (pair #4), and not significant (pair #2).
- the differences between anti-CD40/IL-4/lgM-stimulated naive B cells from young and old subjects are p ⁇ 0.05 for the four pairs.
- the solid line refers to linear regression; the dashed line refers to quadratic regression.
- Figure 5 shows class switch in subsets of B cells.
- B cells from three young subjects were sorted into IgM memory, switch memory, and na ⁇ ve B cell subsets and stimulated (10 4 cells/200 ⁇ l) with anti-CD40/IL-4, alone or together with F(ab') 2 fragments of goat anti-human Ig, for a period of five days.
- Columns show the amounts of AID mRNA (qPCR) which are normalized to GAPDH. Results (mean ⁇ SE) are expressed as percentages of the IgM memory B cells taken as 100%.
- Figure 6 shows that the in vitro AID response of B cells to vaccination decreases with age.
- Regression coefficients before and after vaccination were, respectively: -0.61 and -0.88 (CpG in Fig. 6A); -0.79 and -0.97 (Ag1 in Fig. 6B): -0.83 and -0.94 (Ag2 in Fig. 6C); -0.84 and -0.97 (Ag3 in Fig. 6D). All regression p values are ⁇ 0.05.
- Figure 7 shows that the serum hemaglutinin inactivation (HI) response to vaccination decreases with age.
- Regression coefficient before and after vaccination were, respectively: -0.20 and -0.60 (vaccine in Fig. 7A); 0.07 and -0.023 (Ag1 in Fig. 7B); -0.19 and -0.36 (Ag2 in Fig. 7C); 0.09 and -0.40 (Ag3 in Fig. 7D).
- Figure 8 shows relative AID gene expression in B cells of AID. Subjects were grouped as at risk for type 1 diabetes, new onset of type 1 diabetes, or long term afflicted with type 1 diabetes. Healthy subjects are the control group.
- Figure 9 shows relative IgH gene expression in B cells that have undergone class switching. Subjects were grouped as at risk for type 1 diabetes, new onset of type 1 diabetes, or long term afflicted with type 1 diabetes. Healthy subjects are the control group.
- a B-cell defect in a humoral immune response of a human subject may be predicted or determined.
- B cells may be obtained from the human subject.
- the obtained B cells may or may not be stimulated during in vitro culture; thus, they may be freshly isolated B cells to be analyzed directly ex vivo (i.e., no stimulation during in vitro culture) or stimulated B cells to be analyzed after in vitro culture.
- B cells may or may not be isolated from other cell types prior to analysis.
- Analysis of the B cells involves at least detecting expression of transcription factor E47, activation-induced cytidine deaminase (AID), or an immunoglobulin heavy chain (IgH) that has undergone class switching to IgG, IgE or IgA.
- Reduced expression of E47, AID, IgH that has undergone class switch (or a combination of at least two or all three) as compared to a control indicates that there is a B-cell defect in the humoral immune response.
- the human subject may be less than six months, less than one year, less than two years, less than three years, less than four years, less than five years, more than 50 years, more than 55 years, more than 60 years, more than 65 years, more than 70 years, more than 75 years of age, or any range of ages therebetween.
- the control may be expression of E47, AID or IgH (or a combination of at least two or all three) in B cells obtained from a human aged more than five years, more than ten years, more than 20 years, less than 50 years, less than 40 years, less than 30 years, or any range of the ages therebetween.
- the control may determined by ex vivo or in vitro analysis.
- a biological sample may be obtained from the human subject.
- the biolo- gical sample may be blood (preferably with added anticoagulant such as EDTA, citrate, oxalate, or heparin); mononuclear cells derived therefrom by centrifuga- tion (preferably involving at least density gradient medium) or chromatography (preferably involving at least affinity medium for lymphocytes or a subpopula- tion thereof such as CD19+); or cells isolated from bone marrow, lymph node, spleen, or thymus from the human subject.
- a preservative may be added to the sample to stabilize nucleic acids, proteins, or both of B cells.
- B cells may be stimulated through their CD40 or IL-4 signaling pathway, or both.
- Isolated B cells may be stimulated during in vitro culture with at least antibody specific for a B-cell receptor (e.g., CD40, surface Ig, a Toll-like recep- tor or TLR, a cytokine receptor), a ligand for the B-cell receptor (e.g., CD40L, cognate antigen, CpG, dsRNA, lipopolysaccharide, other pathogen associated molecular pattern or TLR ligand), a cytokine (e.g., TNF- ⁇ , IL-4, IL-5, IL-6), or any combination thereof.
- a B-cell receptor e.g., CD40, surface Ig, a Toll-like recep- tor or TLR, a cytokine receptor
- a ligand for the B-cell receptor e.g., CD40L, cognate antigen, CpG,
- Expression of E47, AID or IgH that has undergone class switching may be detected by measuring RNA or protein using conventional techniques such as run-on transcription, nuclease protection, Northern blotting or real-time PCR, DNA protection or gel retardation, Western blotting, and immunoassay such as ELISA. But the technique used for measurement of nucleic acids or proteins would not need to be specific for this analysis, any known in the art or later developed may be used. Instead of measuring RNA or protein of IgG, IgE or IgA, one or more proxies of class switching (e.g., episome produced by DNA recombination, Ig ⁇ 1 circle transcript, or somatic mutation) may be detected instead.
- proxies of class switching e.g., episome produced by DNA recombination, Ig ⁇ 1 circle transcript, or somatic mutation
- the class switching and/or somatic mutation of antibody produced by B cells may be reduced as compared to control similar to that for E47 or AID.
- the human subject may be or may have been immunized with at least one vaccine (e.g., normally prescribed dose, increased dose, with an adjuvant).
- the subject may be immunized on the same day as obtaining B cells from the subject, or within one week (before or after) of obtaining B cells from him or her.
- the vaccine may be therapeutic or prophylactic.
- the subject may have been or would be immunized with one or more vaccines: e.g., diphtheria, influenza, measles, meningococcal, mumps, pertussis, pneumococcal, rubella, tetanus, varicella, and zoster vaccines.
- the subject may have been or would be immunized with at least a carbohydrate or proteinaceous antigen that induces a humoral immune response against a pathogen (e.g., bacterium or virus) or a cancer (e.g., neoantigen or tumor antigen).
- a pathogen e.g., bacterium or virus
- a cancer e.g., neoantigen or tumor antigen
- the subject may be in need of treatment.
- An increased dose of vaccine may be administered to the subject as compared to a control (e.g., two doses); an adjuvant may be administered with the vaccine (e.g., aluminum salts such as AIOH or AIPO 4 , CpG or dldC, modified lipid A such as MF59, saponins such as QS21 , a squalene emulsion); or both.
- the vaccine e.g., aluminum salts such as AIOH or AIPO 4 , CpG or dldC, modified lipid A such as MF59, saponins such as QS21 , a squalene emulsion
- Elderly human subjects have compromised humoral and cellular immune responses, that lead to reduced protection to infectious agents and to vaccination.
- Currently available vaccines suboptimally protect the elderly population.
- the capacity to class switch the Ig heavy chain is critical to the effectiveness of humoral immune responses in mice and humans.
- E2/ ⁇ -encoded transcription factor E47 which regulates many B cell functions is down-regulated in old splenic B cells. This leads to a reduction in the activation-induced cytidine deaminase (AID), which is known to induce class switch recombination (CSR) and Ig somatic hypermutation (SHM).
- AID activation-induced cytidine deaminase
- CSR class switch recombination
- SHM Ig somatic hypermutation
- the old activated murine B cells also have less AID and less switched antibodies.
- Ig class switch both at the protein and DNA recombinant levels
- AID activation- induced cytidine deaminase, the enzyme necessary to accomplish not only class switch recombination (CSR) but also somatic hypermutation (SHM), necessary for the optimal quality of all Igs
- E47 a transcription factor known to regulate AID
- PBMC peripheral blood mononuclear cells
- the following categories were excluded: established diagnosis of diabe- tes; one or more of the following co-morbid conditions including malignancy (subjects without a recurrence in the last five years have been allowed), congestive heart failure, cardiovascular disease (unstable, less than six months), chronic renal failure, significantly impaired renal or hepatic function, autoimmune diseases, infectious disease, recent (less than three months) trauma or surgery, pregnancy, or documented current substance and/or alcohol abuse.
- the psychological status of all subjects was within normal limits.
- PBMC peripheral blood mononuclear cells
- LSM lymphocyte separation medium ICN Biomedicals
- RPMI 1640 medium
- B cells were isolated from the PBMC as follows. Briefly, cells were washed three times with medium (RPMI 1640) and incubated for 20 min at 4°C with 20 ⁇ l/10 7 cells of anti-CD19 microbeads (Miltenyi Biotech) according to the manufacturer's MiniMacs protocol. Cells were then purified using magnetic columns. At the end of the purification procedure, cells were found to be almost exclusively (>85%) CD19 + by cytofluori- metric analysis: Comparable numbers of CD19+ cells were obtained after negative selection. After the isolation procedure was ended, cells were maintained in serum-free medium for one hour at 4°C in order to minimize potential effects of anti-CD19 antibodies on B cell activation and our parameters are measured 24 hr or later.
- PBMC peripheral blood mononuclear cells
- S cell culture B cells were cultured in complete medium (RPMI 1640, supplemented with 10% fetal calf serum, 10 ⁇ g/ml gentamicin, 2 x 10 "5 M ⁇ -mercaptoethanol, and 2 mM L-glutamine).
- Cells (1 x 10 6 /ml of complete medium) were stimulated in 24-well culture plates with purified anti-human CD40 Abs (BD Pharmingen 555587, 1 ⁇ g/ml), alone or together with recombinant human IL-4 (Biosource PHC0044, 10 ng/ml), for a period of 1 to 7 days.
- sq semiquantitative
- q quantitative
- Memory or na ⁇ ve B cells were stimulated (10 4 cells/200 ⁇ l) in round- bottom 96-well plates with anti-CD40/IL-4, alone or together with F(ab')2 fragments of goat anti-human Ig (2 ⁇ g/ml, Jackson lmmunoresearch 109-006-006) for 1 to 7 days.
- B cells (3-5 x 10 5 /tube) were stained with APC-conjugated anti-CD19 (BD Pharmingen 555415) (all volumes were 20 ⁇ l) for 20 min at 4°C.
- APC-conjugated anti-CD19 (BD Pharmingen 555415) (all volumes were 20 ⁇ l) for 20 min at 4°C.
- IgM memory IgG- /lgA-/CD27+
- switch memory (lgG+/lgA+) B cells
- CD19+ cells (3-5 x 10 5 /tube) were stained with PE-conjugated anti-CD27 (1 :40 diluted, BD Pharmingen 555441 ), biotin-SP-conjugated ChromPure human IgG (Jackson lmmunoresearch 009-060-003), and 20 ⁇ l biotin-SP-conjugated ChromPure human IgA (Jackson lmmunoresearch 009 -06
- ELISA by a sandwich protocol. Briefly, wells of microtiter plates (Nunc 12-565- 136) were coated (overnight at 4°C) with 100 ⁇ l of a purified goat anti-human IgG, F(ab) 2 capture Ab (Jackson lmmunoresearch 109-006-006) at a concentration of 2 ⁇ g/ml in 1x PBS. Reactions were blocked by adding 200 ⁇ l of 1 x PBS containing 10% FCS (blocking buffer) to each well for 30 min at room temperature. Wells were then washed thoroughly with 1x PBS containing 0.05% Tween 20 (washing buffer).
- RNA extraction, reverse transcription, semiquantitative (sq)PCR and quantitative (q)PCR The mRNA was isolated from 0.5x10 4 -10 5 B cells using the ⁇ MACS mRNA isolation kit (Miltenyi Biotech) according to the manufacturer's protocol, eluted into 75 ⁇ l pre-heated elution buffer and stored at -8O 0 C until use.
- RT- PCR was performed in a Mastercycler Eppendorf machine. Briefly, ten ⁇ l of mRNA were used as template for cDNA synthesis in the reverse transcription (RT) reaction.
- the sqPCR was used to determine ⁇ 1 circle transcripts (CTs).
- CTs circle transcripts
- PCR conditions for ⁇ 1 CTs (608 bp) were: denaturation at 94°C for 1 min, amplification of cDNA for 30 cycles, each cycle programmed for denaturation at 94°C for 1 min, annealing at 60 0 C for 1 min, and elongation at 72°C for 1 min followed by a final extension phase at 72 0 C for 3 min.
- Primers were I ⁇ 1 forward 5'-GGG CTT CCA AGC CAA CAG GGC AGG ACA-3 1 (SEQ ID NO:1 ) and C ⁇ reverse 5'-GTT GCC GTT GGG GTG CTG GAC-3' (SEQ ID NO:2).
- PCR primers were: E47 forward, 5'-GCG AGG GCA CCC ACT TC-3' (SEQ ID NO:3); E47 reverse, 5'-GGT CCC AGG AAT GTG GAT GA-3' (SEQ ID NO:4); AID forward, 5'-CAC CGC GCG CCT CTA C-3' (SEQ ID NO:5); AID reverse, 5'-CCT TCC CAG GCT TTG AAA GTT-3' (SEQ ID NO:6); GAPDH forward, 5'-CCA GGT TGT CTC CTC CGA CTT-3' (SEQ ID NO:7); and GAPDH reverse, 5'-CCA GCG TCG AAG GTG GAA-3' (SEQ ID NO:8).
- Primers for E47 were designed with the ABI 7300 software and were selected according to the best penalty score.
- a set of primers for AID (AID forward, 5'-GCC ACG TGG AAT TGC TCT TC-3' SEQ ID NO:9; AID reverse, 5'-AGC GGC CAG GGT CTA GGT-3' SEQ ID NO:10) was initially designed with ABI 7300 software and selected according to the criteria of having the best penalty score. These primers were not optimal, however, in amplifying small amounts of AID such as those found in B cells from elderly people. Therefore, we chose primers for AID (23) but used different conditions, presented here and also checked these for a low penalty score.
- AID activation-induced cytidine deaminase
- IgH immunoglobulin heavy chain
- AID activation-induced cytidine deaminase
- IgH immunoglobulin heavy chain
- First strand cDNA was synthesized from total RNA using a Superscript III First- Strand Synthesis SuperMix for qRT-PCR kit (Invitrogen). cDNA converted from 500 ng of total RNA for each sample was used in the assay. A control sample from a pool of RNA from 22 human tissues (Applied Biosystems) was used for each array to minimize variations between arrays. The control is preamplified from very small quantities of the cDNA using TaqMan PreAmp Master Mix kit (Applied Biosystems). In this way, the same control sample can be used in all of the arrays involved in the study. Data are expressed as the fold change in gene expression normalized to endogenous genes and relative to the control.
- Switch memory B cells decrease whereas the percentage of naive B cells increase with age
- Fig. 1 D Due to the decrease in number and percentage of CD19+ cells, the absolute number of na ⁇ ve B cells is not significantly different in young and old (Fig. 1 D).
- the percentage of IgM memory B cells are not statistically different between young and old (Fig. 1 E, linear curve), but show an increase in old age compared to the middle aged group with the quadratic curve.
- the absolute number of IgM memory B cells decreased with age (Fig. 1 F).
- switch memory B cells decreased in both percentage (Fig. 1 G) and absolute number (Fig. 1 H).
- the significant decrease in switch memory B cells and the increase in percentage of na ⁇ ve and IgM memory B cells suggest an intrinsic defect in the ability of old B cells to undergo CSR. Therefore, we wanted to investigate whether CSR was decreased in CD19+ B cells stimulated in vitro with anti- CD40/IL-4, a stimulus leading to IgG production.
- CSR ⁇ 1 circle transcripts
- BCR B cell receptor
- FIG. 2C shows that IgG levels in culture supernatants decrease with age and, as expected, parallel the data shown in Fig. 2B. Conversely, when we measured IgG levels in serum, we found them increased with age (Fig. 2D) as others have shown consistently (17, 28).
- peripheral blood- derived B cells we have done a few experiments with splenic B cells obtained from cadaveric donors (four subjects, aged 22-52) together with peripheral blood- derived B cells (six subjects, aged 22-53), and shown a similar pattern of IgG production in cultures of anti-CD40/IL-4-stimulated B cells (the 52 year old subject had about 14 of the IgG of the 22 year old subject as seen in the peri- pheral blood-derived B cells, not shown). Therefore, our peripheral blood data are representative of peripheral B lymphocytes.
- Fig. 3A shows that aging decreases AID mRNA expression in anti-CD407IL-4-stimulated CD19+ B cells from subjects of different ages, as determined by sqPCR and qPCR, respectively.
- Sorted cells were also stimulated with anti-CD40/IL-4 and F(ab') 2 fragments of anti-human IgM, used as surrogate antigen, because na ⁇ ve B cells require the activation of the B-cell receptor (BCR) signal transduction to undergo class switch (27).
- Fig. 4 shows that memory B cells express AID in response to anti-CD40/IL-4, independently from the presence of anti-lgM and differentiated into antibody-secreting cells.
- the subset of memory B cells able to class switch in culture is likely the IgM memory population, although here we only looked at AID, and not also CT. As shown in Fig.
- na ⁇ ve B cells do not express AID in response to anti-CD40/IL-4 and up-regulate AID only in the presence of BCR triggering by anti-lgM. Even under the best conditions of stimulation (anti-CD40/IL-4 and anti-lgM), the response of na ⁇ ve B cells was lower than that of memory B cells. Therefore, both IgM memory and na ⁇ ve B cells are negatively affected by aging.
- the old subject in pair #2 (Fig. 4B) is clearly exceptional from the other data in Figs. 3-4.
- Phenotype (% cells) of old #2 is "young-like", (see text).
- switch memory and IgM memory B cells have been shown to proliferate and differentiate into plasma cells in response to anti-CD40/IL-4 (27) but this differentiation would not be expected to increase AID at least in the switch memory cell population.
- na ⁇ ve, IgM memory, and switch memory B cells from young subjects were sorted and found that na ⁇ ve and IgM memory B cells had comparable levels of AID transcripts, whereas switch memory B cells had four-fold less as compared to the other subsets (Fig. 5).
- AID expression to anti-CD40/IL-4 is predominantly measuring the IgM memory cell population.
- the younger age group differed from the older age group (aged greater than 65 years) when analyzed by independent samples f-test for percentage (%) and number (#) (Table II).
- the groups differed on every variable with the exceptions of the numbers of na ⁇ ve B cells and the percentage of IgM memory B cells, which is consistent with the findings above (Figs. 1 B and 1C).
- B cells (10 6 cells/ml), isolated using CD19 magnetic beads from the peripheral blood of subjects of different ages, before (filled circles) or after vaccination (open circles) with 1 ⁇ l of flu vaccine, were cultured with the indicated stimuli, for 7 days. At the end of this time, cells were harvested, RNA was extracted, and qPCR reactions were performed to evaluate AID normalized to GAPDH transcripts. Five ⁇ g of CpG was used to stimulate 1x10 6 B cells for the control in Fig. 6A. Seven subjects (ages 22-71 years) were enrolled to evaluate the age- related effects of influenza vaccination on B cell Ig class switch.
- the blood from these subjects was drawn immediately before vaccination and 4-6 weeks after vaccination.
- the single antigens included in the 2007-2008 (last year) influenza vaccine were: Flu antigen H1 N1 (A/Solomon lslands/3/2006- like), Flu antigen H3N2 (A/Wisconsin/67/2005), and Flu antigen B (B/Malaysia/ 2506/2004).
- B cells subsets of B cells (na ⁇ ve, IgM memory or switch memory B cells); expression of co-stimulatory molecules (CD40, CD80, CD86); and percent of regulatory T cells (CD4+CD25+ or CD8+CD28-).
- Cells were processed as follows. Briefly, B cells were isolated from the peripheral blood by- Ficoll gradient centrifugation using magnetic beads. Cells (1X10 6 /ml) were stimulated in culture for 7 days with CpG (5 ⁇ g/ml), or with the single antigens. AG2 and AG3 (H3N2 and B) were already present in the 2006-2007 vaccine preparation.
- the antigens were used at the concentration of 1 ⁇ g/ml.
- cells were harvested, and mRNA extracted to evaluate AID expression by real-time PCR.
- Results show that influenza vaccination induced up-regulation of AID mRNA expression in all subjects, and in response to all antigens, the up-regulation being higher in young than in old subjects.
- This up-regulation of AID was concomitant with up-regulation of the serum flu- specific IgG response against all antigens in Fig. 6.
- the serum hemaglutinin inactivation (HI) response to flu vaccination decreases with age in Fig. 7.
- Serum was collected from subjects of different ages, before (filled circles) or after vaccination (open circles) with 1 ⁇ l of flu vaccine, and analyzed by HI assay to evaluate antibody production to vaccine or to the single antigens present in the vaccine preparation.
- the HI assay is based on the ability of certain viruses or viral components to hemag- glutinate (HA) the red blood cells of specific animal species. Antibodies specific to influenza can inhibit agglutination. HI is useful for the measurement of anti- body titers of sera.
- the assay is performed as follows. Sera from subjects un- immunized or flu-vaccinated were pre-treated with receptor destroying enzyme (Denke Seiken) for 20 h at 37 0 C.
- receptor destroying enzyme Denke Seiken
- Figs. 6 and 7 show that AID gene expression is a good biomarker for predicting the effectiveness of flu vaccination.
- RT-PCR gene expression levels by RT-PCR for three different categories of human subjects "at risk" for type 1 diabetes, with new onset of type 1 diabetes, or having long-term type 1 diabetes to healthy human subjects as a negative control. Both AID and IgH that has undergone class switching were measured for gene expression.
- RT-PCR was done using resting whole blood as the RNA source. No stimulation or culturing was required prior to analysis of gene expression.
- Figs. 8 and 8 show that assaying for gene expression of biomarkers has utility outside of the context of vaccination. In vitro stimulation and culturing of B cells prior to analysis is not required. Discussion
- peripheral blood-derived B cells and splenic B cells are less able to produce IgG in response to anti-CD40/IL-4. These facts may be explained by the initial antigenic stimulation being defective in aged B cells. This is a major point of our studies. The accumulation in the sera of IgG, not from these types of cells, likely comes from plasmablasts (many in the bone marrow) (31 , 32) secreting immunoglobulin of suboptimal quality both in affinity and polyclonality (and autoimmune immunoglobulin (33)).
- mice (8, 9) that the E2>A-encoded transcription factor E47 is down-regulated in old splenic activated B cells, leading to a reduction in the activation-induced cytidine deaminase (AID) and in CSR. This leads to reduced amounts of switched antibodies.
- AID activation-induced cytidine deaminase
- CSR CSR-induced cytidine deaminase
- E47 is also reduced in human B cells and this leads to reduced AID, CTs and IgG released in culture supernatants.
- E47 has been shown to be necessary for CSR (39-41 ) and SHM (39) as it transcriptionally regulates the gene for activation-induced cytidine deaminase (AID) (42). Therefore, E47 has a relevant role in all processes generating antibody diversity, such as V(D)J recombination (43-48), CSR and SHM.
- Our results herein clearly indicate that intrinsic defects in the B cell may have a crucial role in the generation of an effective humoral immune response in sensecence.
- our results show an intrinsic defect in the ability of old B cells to undergo CSR.
- the transcription factor E47 in activated B cells is significantly impaired by aging. This leads to a reduction in AID and, in turn, to less switched antibodies produced by the activated B cells.
- E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Human biomarkers (i.e., E47, AID or IgH that has undergone class switching) are described that characterize the immune potential of B lymphocytes, which produce immunoglobulins (Ig), and their ability to respond to infections by a pathogen or a vaccine. A reduction in one, any two or all three may be diagnostic of an intrinsic B-cell defect in a humoral immune response.
Description
HUMAN BIOMARKERS FOR DETERMINING INTRINSIC B-CELL DEFECTS
CROSS-REFERENCE TO RELATED APPLICATION This application claims the benefit of Application No. 61/030,794, filed February 22, 2008.
FEDERALLY-SPONSORED RESEARCH OR DEVELOPMENT The U.S. Government has certain rights in this invention as provided for by contract NIH-R21-AG28586 from the Department of Health and Human Services.
BACKGROUND OF THE INVENTION
This invention relates to human biomarkers (i.e., E47, AID, IgH that has undergone class switching), which characterize the immune potential of B lymphocytes, which produce immunoglobulins (Ig), and their ability to respond to infections by pathogens and vaccines.
Aging affects the humoral immune response in humans both quantitatively and qualitatively with reduced antibody specificity, affinity, and isotype switch (1-3). The changes in the humoral immune response during aging significantly contribute to the increased susceptibility of the elderly to infectious diseases and reduce the protective effects of vaccination. The decreased ability of aged subjects to produce high affinity protective antibody responses against infectious agents or experimental antigens likely also results from additional defects in required T-cell signaling to B cells (4-6). Although B-cell function may suffer from lack of a good T-cell help in aging, intrinsic changes in B cells also occur and have a significant impact on antibody production and somatic mutation (3, 7-9).
During an immune response, B cells can switch the expression of surface Ig from IgM to IgG, IgE, or IgA. This DNA recombination takes place between two switch (S) regions, one located immediately upstream (51) of the μ CH (donor site) and one 5' of one of the other CH regions (γ, ε or α) (acceptor site) to produce IgG, IgE or IgA. The CSR requires chromatin opening of S
regions, recognition and cleavage of the target DNA by an endonuclease and repair and ligation of the cleaved ends (10-15). CSR is extremely important for the humoral immune response, because it generates antibodies of the same specificity, but with different effector functions. In vitro, human naive B cells can be activated to undergo CSR with anti-CD40 or CD40L, together with cytokine signals which can direct CSR to distinct classes. The critical role of CD40- CD40L interaction for CSR is provided by the discovery that mutations in either the CD40 or CD40L (CD154) gene cause the hyper IgM (HIGM) syndrome, HIGM3 or HIGM1 , respectively, characterized by very low levels of serum IgG, IgA, and IgE, with normal or elevated IgM, associated with defective germinal center formation (16).
Human B cell numbers and percentages have been shown to decrease significantly with age (17, 18). It has also been shown that the percentage of IgM memory B cells, which are responsible for the response to S. pneumoniae infection, is significantly decreased whereas that of naϊve B cells is increased in old subjects (19). The reduction in IgM cells has been suggested to cause reduced specific antibody titers in elderly subjects vaccinated against pneumococcal polysaccharides. Others have shown that the percentage of CD27+ memory B cells increases with age, but this increase is not significant (20). Also in the human tonsil, naϊve B cells have been shown to increase with age (21 ). In mice, the number of peripheral B cells is not decreased with age. This discrepancy between humans and mice likely reflects different mechanisms to maintain the number of B cells, possibly by increasing their survival in mice (22). So far, to our knowledge, no one has studied age-related changes in naϊve and memory B cells in mice, probably because good memory B cell markers in the mouse system were not available (cf. CD27 in human).
We have previously shown , only in mice (8, 9) that the E2/\-encoded transcription factor E47 is down-regulated in old splenic B cells, leading to a reduction in AID and in CSR. This intrinsic defect in old splenic B cells gene- rates reduced amounts of switched antibodies. We have extended our study to investigate whether aging also affects antibody production and both E47 and AID expression in B cells isolated from the peripheral blood of human subjects
(18 to 86 years). Results herein show that the expression of E47, AID and CSR progressively decrease with age. We also show that an age-related decline in the number and percentage of switch memory B cells, no change in the percentage but a decline in the number of IgM memory B cells, and an increase in the percentage but not in the number of naϊve B cells, consistent with our data on the decrease seen in CSR in vitro. In addition, we suggest that the subsets of B cells able to class switch in culture are the naϊve and the IgM memory populations. Our results provide possible molecular mechanisms for an intrinsic decrease in B-cell function and the humoral immune response in aging. At the time this invention was made, there was no reasonable expectation from our prior work in mice that such results would be obtained in human subjects.
Therefore, it is an objective of the present invention to provide biomar- kers for determining intrinsic B-cell defects in a humoral immune response of a human subject. A long-felt need is addressed thereby. Other advantages and improvements are described below or would be apparent from the disclosure herein.
SUMMARY OF THE INVENTION The invention provides biomarkers for predicting or determining whether there is an intrinsic defect in the B cells participating in a humoral immune response of a human subject. The subject may have reduced immunocompe- tence because of age (e.g., less than 3 or more than 65 years of age), disease or treatment of a disease, a genetic defect, suppression of the immune system, etc. Although reduction in B-cell expression of a single biomarker may be suffi- cient for predicting or determining whether there is an intrinsic B-cell defect, it could also be required that at least two of the biomarkers or all three (i.e., E47, AID and IgH that has undergone class switching) are reduced.
In particular, a method of the invention may include one or more of the following: obtaining a biological sample, which contains B cells, from a human subject; optionally, isolating B cells from the biological sample (i.e., the method may detect expression from a biological sample that was neither fractionated nor selected for cell subpopulations); optionally, stimulating in vitro B cells to
divide and differentiate at least some B cells being cultured (i.e., the method may detect expression in a biological sample or cell subpopulation that was not stimulated or cultured in vitro) or, alternatively, freshly isolated B cells are analyzed ex vivo without being stimulated during in vitro culture; and detecting expression in the B cells of transcription factor E47, activation-induced cytidine deaminase (AID), or an immunoglobulin heavy chain (IgH) that has undergone class switching to IgG, IgE or IgA. As an alternative to detecting expression of IgH that has undergone class switching, other proxies for the IgH biomarker may be detected in B cells such as episomes produced by DNA recombination, Igγ1 circle transcripts, or somatic mutation. Therefore, only obtaining a biological sample and detecting expression of a biomarker in B cells are required in the method. In some embodiments, antibody production may not be measured. A human subject may be or may have been immunized with a vaccine. The subject may be a resident in a healthcare or assisted living facility, a reci- pient of a solid organ transplant or renal dialysis, afflicted by a chronic cardiovascular or pulmonary disorder, at risk for or affected by autoimmune disease (e.g., type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, especially those with a significant B-cell component involved in pathogenesis), immunocompromised or immunosuppressed, etc. in need of treatment. Alternatively, the subject may be young and needing a series of childhood immunizations. Having an intrinsic B-cell defect in the subject may be used to stage disease or to recommend treatment at an early or late stage of disease pathogenesis.
Further objectives and advantages aspects of the invention will be apparent to a person skilled in the art from the following description of specific embodiments and the claims, and generalizations thereto.
DESCRIPTION OF THE DRAWINGS
Figure 1 shows age-related changes in B-cell percentages and numbers. B cells isolated from the peripheral blood (PBMC) of subjects of different ages using CD19 magnetic beads, were analyzed for percentage of cells expressing membrane CD19 (Fig. 1A), and absolute number of CD19+ cells calculated
(Fig. 1B). Similarly, the percentages of naive (lgG-/lgA-/ CD27-) B cells, IgM memory (lgG-/lgA-/CD27+) B cells, and switch memory (lgG+/lgA+/CD27+) B cells are shown in Figs. 1 C, 1 E and 1 G, respectively, and the numbers of naϊve (lgG-/lgA-/ CD27-) B cells, IgM memory (lgG-/lgA-/CD27+) B cells, and switch memory (lgG+/lgA+/CD27+) B cells are shown in Figs. 1 D, 1 F and 1 H, respectively. The Pearson's r value for a linear correlation between age and these immune variables, as well as its statistical significance are as follows: B cell numbers: r = -0.68, p = 0.001 ; B-cell percentages: r = -0.64, p = 0.001 ; naϊve B cell numbers: r = 0.19, p = 0.31 ; naϊve B cell percentages r = 0.54, p = 0.002; IgM memory B cell numbers: r = 0.67, p = 0.001 ; IgM memory B cell percentages: r = -0.23, p = 0.220; switch memory B cell numbers, r = 0.726, p = 0.001 ; and switch memory B cell percentages: r = -0.48, p = 0.003. Naϊve B-cell and IgM memory B-cell percentages showed significant quadratic relationships to age. The quadratic, non-linear coefficient betas are, respectively: -2.519 {t- value = -2.561 , p = 0.016) and 2.64 (f-value = 2.279, p = 0.03). Significant differences between young and old are indicated by *(p < 0.05) and **(p < 0.01 ). The solid line refers to linear regression; the dashed line refers to quadratic regression.
Figure 2 shows aging decreases class switch in activated peripheral blood-derived human B cells. B cells (106 cells/ml), isolated from the peripheral blood of subjects of different ages using CD19 magnetic beads, were cultured with anti-CD40 (1 μg/ml) and IL-4 (10 ng/ml), for a period of 6 to 7 days. At the end of this period, cells were harvested, RNA was extracted, and sqPCR reactions were performed to evaluate CTs and GAPDH transcripts. Undiluted and 1 :4 diluted RT-PCR from five representative subjects are shown in Fig. 2A. Densitometric analyses (arbitrary units) of CTs, normalized to GAPDH, from 46 subjects of different ages are shown in Fig. 2B. The numbers shown for each sample are percentages of the highest value (randomly chosen) normalized to 100. The Pearson's r value for a linear correlation between age and these immune variables, as well as its statistical significance are r = -0.84, p = 0.001. In Fig. 2C, B cells were cultured as described above. IgG level in culture super- natants were determined by ELISA. The Pearson's r value for correlations
between age and this immune variable, as well as its statistical significance are r = -0.75, p = 0.001. In Fig. 2D, the IgG levels in serum were determined by ELISA. The Pearson's r value for correlations between age and this immune variable, as well as its statistical significance are r = 0.572, p = 0.001 . The solid line refers to linear regression; the dashed line refers to quadratic regression.
Figure 3 shows aging decreases AID mRNA expression in activated peripheral blood-derived human B cells. B cells (106 cells/ml), isolated from the peripheral blood of subjects of different ages using CD19 magnetic beads, were cultured with anti-CD40 (1 μg/ml) and IL-4 (10 ng/ml), for a period of 6 to 7 days. At the end of this period, cells were harvested, RNA was extracted, and sqPCR reactions were performed to evaluate AID and GAPDH transcripts. The graph in Fig. 3A shows the amounts of AID mRNA, normalized to GAPDH, from 34 subjects of different ages. These are 34 out of the 46 evaluated by sqPCR (not shown). Values for seven subjects between the ages of 67 and 79 were undetectable (at the x axis). Numbers are percentages of the highest value (randomly chosen) normalized to 100%. The Pearson's r value for a linear correlation between age and these immune variables, as well as its statistical significance are: r = -0.78, p = 0.001. AID mRNA expression showed significant quadratic relations to age. Quadratic, non-linear coefficient betas were the same for qPCR. Alternatively, B cells (106 cells/ml) were cultured as above but for only one day (optimal timepoint for E47 mRNA expression). The graph in Fig. 3B shows the amounts of E47 mRNA, normalized to GAPDH, from 34 subjects of different ages. These are 30 out of the 46 evaluated by sqPCR (not shown). The Pearson's r value are: r = -0.75, p = 0.001 . E47 mRNA expression also showed significant quadratic relations to age. The quadratic, non-linear coefficient betas were: -1 .866 (f-va!ue = -2.745, p = 0.009). In Fig. 3C, sqPCR data for E47 and AID were positively correlated. Correlation is significant at the 0.01 level (2-tailed). The solid line refers to linear regression; the dashed line refers to quadratic regression. Figure 4 shows both memory and naive B cells are impaired in their ability to undergo in vitro class switch. Sorted memory (CD19+CD27+) B cells or naive (CD19+CD27-) B cells were stimulated (104 cells/200 μl) with anti-
CD40/IL-4, alone or together with F(ab')2 fragments of goat anti-human Ig, for a period of five days (at later times, viability in culture significantly dropped off). The graphs in Figs. 4A, 4B, 4C and 4D show amounts of AID mRNA (qPCR) which are normalized to GAPDH1 expressed as ΔCts from four pairs of young (white columns) and old (black columns) subjects. For each pair, results are expressed as percentages of the anti-CD40/IL-4-stimulated memory B cells from young subjects taken as 100. Ages of young #1 , 2, 3 and 4 were 20, 21 , 24 and 23 years and those of old #1 , 2, 3 and 4 were 72, 82, 74 and 71 years. These subjects are not represented in Fig. 3. The differences between anti- CD40/IL-4-stimulated memory B cells from young and old subjects (columns 1 vs. 5) are p < 0.05 for the four pairs, and between anti-CD40/IL-4/lgM-stimu- lated memory B cells from young and old subjects (columns 2 vs. 6) are p < 0.01 (pairs #1 and #3), p < 0.05 (pair #4), and not significant (pair #2). The differences between anti-CD40/IL-4/lgM-stimulated naive B cells from young and old subjects (columns 4 vs. 8) are p < 0.05 for the four pairs. The solid line refers to linear regression; the dashed line refers to quadratic regression.
Figure 5 shows class switch in subsets of B cells. B cells from three young subjects were sorted into IgM memory, switch memory, and naϊve B cell subsets and stimulated (104 cells/200 μl) with anti-CD40/IL-4, alone or together with F(ab')2 fragments of goat anti-human Ig, for a period of five days. Columns show the amounts of AID mRNA (qPCR) which are normalized to GAPDH. Results (mean ± SE) are expressed as percentages of the IgM memory B cells taken as 100%.
Figure 6 shows that the in vitro AID response of B cells to vaccination decreases with age. Regression coefficients before and after vaccination were, respectively: -0.61 and -0.88 (CpG in Fig. 6A); -0.79 and -0.97 (Ag1 in Fig. 6B): -0.83 and -0.94 (Ag2 in Fig. 6C); -0.84 and -0.97 (Ag3 in Fig. 6D). All regression p values are < 0.05.
Figure 7 shows that the serum hemaglutinin inactivation (HI) response to vaccination decreases with age. Regression coefficient before and after vaccination were, respectively: -0.20 and -0.60 (vaccine in Fig. 7A); 0.07 and -0.023 (Ag1 in Fig. 7B); -0.19 and -0.36 (Ag2 in Fig. 7C); 0.09 and -0.40 (Ag3 in Fig.
7D). p values of the regressions before and after vaccination were, respectively p = 0.23 and p < 0.05 (vaccine); p = 0.84 and p = 0.25 (Ag1 ): p = 0.05 and p = 0.06 (Ag2); p = 0.81 p = 0.05 (Ag3).
Figure 8 shows relative AID gene expression in B cells of AID. Subjects were grouped as at risk for type 1 diabetes, new onset of type 1 diabetes, or long term afflicted with type 1 diabetes. Healthy subjects are the control group.
Figure 9 shows relative IgH gene expression in B cells that have undergone class switching. Subjects were grouped as at risk for type 1 diabetes, new onset of type 1 diabetes, or long term afflicted with type 1 diabetes. Healthy subjects are the control group.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
In a specific embodiment, a B-cell defect in a humoral immune response of a human subject may be predicted or determined. B cells may be obtained from the human subject. The obtained B cells may or may not be stimulated during in vitro culture; thus, they may be freshly isolated B cells to be analyzed directly ex vivo (i.e., no stimulation during in vitro culture) or stimulated B cells to be analyzed after in vitro culture. B cells may or may not be isolated from other cell types prior to analysis. Analysis of the B cells involves at least detecting expression of transcription factor E47, activation-induced cytidine deaminase (AID), or an immunoglobulin heavy chain (IgH) that has undergone class switching to IgG, IgE or IgA. Reduced expression of E47, AID, IgH that has undergone class switch (or a combination of at least two or all three) as compared to a control indicates that there is a B-cell defect in the humoral immune response.
The human subject may be less than six months, less than one year, less than two years, less than three years, less than four years, less than five years, more than 50 years, more than 55 years, more than 60 years, more than 65 years, more than 70 years, more than 75 years of age, or any range of ages therebetween.
The control may be expression of E47, AID or IgH (or a combination of at least two or all three) in B cells obtained from a human aged more than five
years, more than ten years, more than 20 years, less than 50 years, less than 40 years, less than 30 years, or any range of the ages therebetween. The control may determined by ex vivo or in vitro analysis.
A biological sample may be obtained from the human subject. The biolo- gical sample may be blood (preferably with added anticoagulant such as EDTA, citrate, oxalate, or heparin); mononuclear cells derived therefrom by centrifuga- tion (preferably involving at least density gradient medium) or chromatography (preferably involving at least affinity medium for lymphocytes or a subpopula- tion thereof such as CD19+); or cells isolated from bone marrow, lymph node, spleen, or thymus from the human subject. A preservative may be added to the sample to stabilize nucleic acids, proteins, or both of B cells.
B cells may be stimulated through their CD40 or IL-4 signaling pathway, or both. Isolated B cells may be stimulated during in vitro culture with at least antibody specific for a B-cell receptor (e.g., CD40, surface Ig, a Toll-like recep- tor or TLR, a cytokine receptor), a ligand for the B-cell receptor (e.g., CD40L, cognate antigen, CpG, dsRNA, lipopolysaccharide, other pathogen associated molecular pattern or TLR ligand), a cytokine (e.g., TNF-α, IL-4, IL-5, IL-6), or any combination thereof.
Expression of E47, AID or IgH that has undergone class switching may be detected by measuring RNA or protein using conventional techniques such as run-on transcription, nuclease protection, Northern blotting or real-time PCR, DNA protection or gel retardation, Western blotting, and immunoassay such as ELISA. But the technique used for measurement of nucleic acids or proteins would not need to be specific for this analysis, any known in the art or later developed may be used. Instead of measuring RNA or protein of IgG, IgE or IgA, one or more proxies of class switching (e.g., episome produced by DNA recombination, Igγ1 circle transcript, or somatic mutation) may be detected instead. The class switching and/or somatic mutation of antibody produced by B cells may be reduced as compared to control similar to that for E47 or AID. The human subject may be or may have been immunized with at least one vaccine (e.g., normally prescribed dose, increased dose, with an adjuvant). The subject may be immunized on the same day as obtaining B cells from the
subject, or within one week (before or after) of obtaining B cells from him or her. The vaccine may be therapeutic or prophylactic. For example, the subject may have been or would be immunized with one or more vaccines: e.g., diphtheria, influenza, measles, meningococcal, mumps, pertussis, pneumococcal, rubella, tetanus, varicella, and zoster vaccines. The subject may have been or would be immunized with at least a carbohydrate or proteinaceous antigen that induces a humoral immune response against a pathogen (e.g., bacterium or virus) or a cancer (e.g., neoantigen or tumor antigen).
For a human subject predicted or determined to have a B-cell defect in the humoral immune response, the subject may be in need of treatment. An increased dose of vaccine may be administered to the subject as compared to a control (e.g., two doses); an adjuvant may be administered with the vaccine (e.g., aluminum salts such as AIOH or AIPO4, CpG or dldC, modified lipid A such as MF59, saponins such as QS21 , a squalene emulsion); or both. Elderly human subjects have compromised humoral and cellular immune responses, that lead to reduced protection to infectious agents and to vaccination. Currently available vaccines suboptimally protect the elderly population. The capacity to class switch the Ig heavy chain is critical to the effectiveness of humoral immune responses in mice and humans. We have previously shown in mice that the E2/\-encoded transcription factor E47, which regulates many B cell functions is down-regulated in old splenic B cells. This leads to a reduction in the activation-induced cytidine deaminase (AID), which is known to induce class switch recombination (CSR) and Ig somatic hypermutation (SHM). The old activated murine B cells also have less AID and less switched antibodies. We have extended our study here to investigate whether aging also affects antibody production, E47 and AID expression in B cells isolated from the peripheral blood (PB) of human subjects (18 to 86 years). Our results obtained with activated CD19+ B cells show that the expression of E47, AID and Igγ1 circle transcripts progressively decrease with age. We also show an age-related decline in the percentage of switch memory B cells (lgG+/lgA+/CD27+), an increase in that of naive B cells (lgG-/lgA-/CD27-) for most individuals and no
decrease in that of IgM memory cells in PB, consistent with our data on the decrease seen in CSR in vitro.
EXAMPLES B lymphocytes purified from peripheral blood of human subjects aged primarily over 65 years, which were stimulated in vitro with various stimuli (e.g., anti-CD40 plus IL-4), have suboptimal response as measured by Ig class switch (both at the protein and DNA recombinant levels), AID (activation- induced cytidine deaminase, the enzyme necessary to accomplish not only class switch recombination (CSR) but also somatic hypermutation (SHM), necessary for the optimal quality of all Igs), and E47 (a transcription factor known to regulate AID). We also describe the unique primers used to optimally amplify E47 and AID by semi-quantitative and quantitative (real time) RT-PCR. We have previously published similar results in mice, but this is the first demon- stration of (1 ) intrinsic B-cell defects in aged humans and, more specifically, (2) specific combinations of biological markers to easily classify the "goodness" of a human B-cell response.
Subjects Peripheral blood mononuclear cells (PBMC) were isolated from healthy human volunteers of different ages (18 to 86 years) after appropriate signed consent. Initial experiments to optimize the conditions for cell isolation and culture were performed with spleen cells from human cadavers (20 to 56 years) from the Department of Surgery, Division of Transplantation of the University of Miami Miller School of Medicine. Cadaveric spleen cells were used to optimize the conditions for B cell preparation and culture. The subjects participating in the study were screened for diseases known to alter the immune response or for consumption of medications that could alter the immune response. In particular, the following categories were excluded: established diagnosis of diabe- tes; one or more of the following co-morbid conditions including malignancy (subjects without a recurrence in the last five years have been allowed), congestive heart failure, cardiovascular disease (unstable, less than six
months), chronic renal failure, significantly impaired renal or hepatic function, autoimmune diseases, infectious disease, recent (less than three months) trauma or surgery, pregnancy, or documented current substance and/or alcohol abuse. The psychological status of all subjects was within normal limits. Partici- pants were 46 healthy subjects (mean age = 51.3; SD = 19.2). There were 25 females and 21 males in this sample. Two were Asian, 14 were Black, and 30 were White (13 identified themselves as Hispanic Whites). We have achieved highly significant differences between samples from young and old subjects, even before reaching the number of 46 subjects. Statistical analysis (f-test) showed that there were no differences between male and female subjects on any of the parameters measured in this study (all p values > 0.60). Similarly, no differences were noted between subjects of different ethnicities or races in ANOVA analyses (all p values > 0.20).
B cell enrichment
PBMC were collected by density gradient centrifugation on LSM lymphocyte separation medium (ICN Biomedicals). Cells were then washed three times with medium (RPMI 1640). B cells were isolated from the PBMC as follows. Briefly, cells were washed three times with medium (RPMI 1640) and incubated for 20 min at 4°C with 20 μl/107 cells of anti-CD19 microbeads (Miltenyi Biotech) according to the manufacturer's MiniMacs protocol. Cells were then purified using magnetic columns. At the end of the purification procedure, cells were found to be almost exclusively (>85%) CD19+ by cytofluori- metric analysis: Comparable numbers of CD19+ cells were obtained after negative selection. After the isolation procedure was ended, cells were maintained in serum-free medium for one hour at 4°C in order to minimize potential effects of anti-CD19 antibodies on B cell activation and our parameters are measured 24 hr or later.
Cell sorting
To evaluate which cell subset was responsible for class switching in the whole CD19+ B cell population, PBMC were sorted into memory (CD19+CD27+)
B cells or naive (CD19+CD27") B cells. Cells were separated with a FACS ARIA cell sorter (BD Biosciences). Cell preparations were typically >98% pure.
S cell culture B cells were cultured in complete medium (RPMI 1640, supplemented with 10% fetal calf serum, 10 μg/ml gentamicin, 2 x 10"5 M β-mercaptoethanol, and 2 mM L-glutamine). Cells (1 x 106/ml of complete medium) were stimulated in 24-well culture plates with purified anti-human CD40 Abs (BD Pharmingen 555587, 1 μg/ml), alone or together with recombinant human IL-4 (Biosource PHC0044, 10 ng/ml), for a period of 1 to 7 days. At the end of this time period, cells were harvested, RNA was extracted from cells for semiquantitative (sq) or quantitative (q) RT-PCR, and supernatants were collected for ELISA. In four of the elderly subjects (> 65 years), total PBMC were stimulated because of extremely low numbers of B cells. Only B cells were stimulated by this proce- dure.
Memory or naϊve B cells were stimulated (104 cells/200 μl) in round- bottom 96-well plates with anti-CD40/IL-4, alone or together with F(ab')2 fragments of goat anti-human Ig (2 μg/ml, Jackson lmmunoresearch 109-006-006) for 1 to 7 days.
Flow cytometry
After magnetic enrichment, B cells (3-5 x 105/tube) were stained with APC-conjugated anti-CD19 (BD Pharmingen 555415) (all volumes were 20 μl) for 20 min at 4°C. To detect naive (lgG-/lgA-/CD27-) B cells, IgM memory (IgG- /lgA-/CD27+) B cells, or switch memory (lgG+/lgA+) B cells, CD19+ cells (3-5 x 105/tube) were stained with PE-conjugated anti-CD27 (1 :40 diluted, BD Pharmingen 555441 ), biotin-SP-conjugated ChromPure human IgG (Jackson lmmunoresearch 009-060-003), and 20 μl biotin-SP-conjugated ChromPure human IgA (Jackson lmmunoresearch 009 -060-011 ). After washings, biotin-conjugated antibodies were revealed with APC-conjugated streptavidin (1 :40 diluted, BD Pharmingen 554067). Samples of 3-5 x 105 cells were analyzed on an LSR flow cytometer (BD Biosciences) using logarithmic amplification. For four-color
analysis, controls were included in every experiment to determine background fluorescence.
ELISA Human IgGs were titrated in the collected supernatants and sera by
ELISA by a sandwich protocol. Briefly, wells of microtiter plates (Nunc 12-565- 136) were coated (overnight at 4°C) with 100 μl of a purified goat anti-human IgG, F(ab)2 capture Ab (Jackson lmmunoresearch 109-006-006) at a concentration of 2 μg/ml in 1x PBS. Reactions were blocked by adding 200 μl of 1 x PBS containing 10% FCS (blocking buffer) to each well for 30 min at room temperature. Wells were then washed thoroughly with 1x PBS containing 0.05% Tween 20 (washing buffer). Serial dilutions of the culture supernatants or an IgG standard (human IgG whole molecule, Jackson lmmunoresearch 009-000- 003) at a concentration of 1120 ng/ml in blocking buffer were added to the wells (100 μl/well), and incubated overnight at 4°C. Wells were washed thoroughly with washing buffer before receiving 100 μl/well of the detecting Ab (anti-human IgG-HRP, BD Biosciences 555788), at a 1 :5000 dilution in blocking buffer. After one hour incubation at room temperature, wells were washed and given 100 μl of the substrate solution (TMB chromogen, Biosource SB01 ). Wells were incu- bated 15 to 20 min at room temperature to allow reactions to develop. Well contents were measured for absorbance at 405 nm.
RNA extraction, reverse transcription, semiquantitative (sq)PCR and quantitative (q)PCR The mRNA was isolated from 0.5x104-105 B cells using the μMACS mRNA isolation kit (Miltenyi Biotech) according to the manufacturer's protocol, eluted into 75 μl pre-heated elution buffer and stored at -8O0C until use. RT- PCR was performed in a Mastercycler Eppendorf machine. Briefly, ten μl of mRNA were used as template for cDNA synthesis in the reverse transcription (RT) reaction.
The sqPCR was used to determine γ1 circle transcripts (CTs). PCR conditions for γ1 CTs (608 bp) were: denaturation at 94°C for 1 min, amplification of
cDNA for 30 cycles, each cycle programmed for denaturation at 94°C for 1 min, annealing at 600C for 1 min, and elongation at 72°C for 1 min followed by a final extension phase at 720C for 3 min. Primers were Iγ1 forward 5'-GGG CTT CCA AGC CAA CAG GGC AGG ACA-31 (SEQ ID NO:1 ) and Cμ reverse 5'-GTT GCC GTT GGG GTG CTG GAC-3' (SEQ ID NO:2). Conditions and primers for GAPDH have been published previously (8, 9). PCR products were separated on 1.5% agarose gels. Gels were visualized using the Alphalmager Enhanced Resolution Gel Documentation and Analysis System (Alpha Innotech) and images were quantitated using the AlphaEaseFC 32-bit software. During the course of these studies, analysis was switched from sqPCR to qPCR for the measurement of E47 and AID, with results being consistent with both techniques. To perform quantitative qPCR, 2 μl of cDNAs were added to 8 μl of 2x SYBR Green PCR Master Mix (ABI 4367659), 1 μl of 5 μM forward primer, 1 μl of 5 μM reverse primer, and deionized water in a final volume of 20 μl. Reactions were conducted in MicroAmp 96-well plates (ABI N8010560). Calculations were made with ABI software. Briefly, we determined the cycle number at which transcripts reached a significant threshold (Ct) for E47, AID, and GAPDH as control. A value of the target gene (E47 or AID), relative to GAPDH, was calculated and expressed as ΔCt. Samples are expressed as percentages of the highest ΔCt value normalized to 100. PCR primers were: E47 forward, 5'-GCG AGG GCA CCC ACT TC-3' (SEQ ID NO:3); E47 reverse, 5'-GGT CCC AGG AAT GTG GAT GA-3' (SEQ ID NO:4); AID forward, 5'-CAC CGC GCG CCT CTA C-3' (SEQ ID NO:5); AID reverse, 5'-CCT TCC CAG GCT TTG AAA GTT-3' (SEQ ID NO:6); GAPDH forward, 5'-CCA GGT TGT CTC CTC CGA CTT-3' (SEQ ID NO:7); and GAPDH reverse, 5'-CCA GCG TCG AAG GTG GAA-3' (SEQ ID NO:8). Primers for E47 were designed with the ABI 7300 software and were selected according to the best penalty score. A set of primers for AID (AID forward, 5'-GCC ACG TGG AAT TGC TCT TC-3' SEQ ID NO:9; AID reverse, 5'-AGC GGC CAG GGT CTA GGT-3' SEQ ID NO:10) was initially designed with ABI 7300 software and selected according to the criteria of having the best penalty score. These primers were not optimal, however, in amplifying small amounts of AID such as those found in B cells from elderly
people. Therefore, we chose primers for AID (23) but used different conditions, presented here and also checked these for a low penalty score. Conditions for both E47 and AID were: 500C for 2 min, 55°C for 10 min, 95°C for 15 sec (40 cycles), and 600C for 1 min. Because the primers for CTs gave a high penalty score, we measured CTs by sqPCR only.
Assessment of multiple gene expression levels
Gene expression levels of activation-induced cytidine deaminase (AID) and immunoglobulin heavy chain (IgH) that has undergone class switching in the peripheral blood was monitored by using a custom-made TaqMan low- density array with a 7900HT fast real-time PCR system (Applied Biosystems). Individual TaqMan assays for these genes was pre-loaded in triplicate into the array's 384 wells of a microfluidic card. Control genes (i.e., 18S rRNA and β- actin) were also included on the card. Several different cDNA samples can be analyzed at the same time using the card in a multiplex assay. Total RNA was extracted from whole blood collected into PAXgene Blood RNA tubes (Qiagen). First strand cDNA was synthesized from total RNA using a Superscript III First- Strand Synthesis SuperMix for qRT-PCR kit (Invitrogen). cDNA converted from 500 ng of total RNA for each sample was used in the assay. A control sample from a pool of RNA from 22 human tissues (Applied Biosystems) was used for each array to minimize variations between arrays. The control is preamplified from very small quantities of the cDNA using TaqMan PreAmp Master Mix kit (Applied Biosystems). In this way, the same control sample can be used in all of the arrays involved in the study. Data are expressed as the fold change in gene expression normalized to endogenous genes and relative to the control.
Statistical analyses
Before conducting the main analyses, we examined the data for normality of the distribution and outliers. Four outliers were observed but there was no discernible pattern to these outliers. Outliers were scores with more than two standard deviations above and below the mean. For these four variables, the score was changed to the mean score in order to ensure a normal distribution
for conducting the parametric statistical analyses. Linear correlations between age and the following immune parameters were calculated: B-cell percentages and numbers, B-cell subset percentages and numbers, CTs1 AID, E47, and IgG in culture supernatants. Because the graphical representations of these rela- tionships had a non-linear appearance, we also examined non-linear (i.e., quadratic) relationships between age and immune parameters. That is, a non-linear relationship might postulate that middle aged are higher than expected by linear curve. Values are shown in each figure legend.
Switch memory B cells decrease whereas the percentage of naive B cells increase with age
We analyzed the composition of the peripheral B-cell pool in 46 subjects of different ages (18 to 86 years): i.e., numbers and percentages of total CD19+ B cells, as well as numbers and percentages of naive (lgG-/lgA-/CD27-) B cells, IgM memory (lgG-/lgA-/CD27+) B cells, or switch memory (lgG+/lgA+) B cells. Percentage and absolute number of CD19+ B cells from peripheral blood mononuclear cells (PBMC) are shown in the Figs. 1A and 1 B, respectively. We decided to analyze lgG+/lgA+ cells as switch memory B cells because, in addition to the lgG+/lgA+/CD27+ population, a fraction of lgG+/lgA+/CD27- B cells also expresses mutated IgV region genes, increased expression of the costimu- latory molecules CD80 andcentages of total CD19+ B cells decrease with age, consistent with data previously published (19, 25). The percentage of naive B cells increases with age (Fig. 1 C) at least for most of the subjects tested (such that the linear curve accounted for greater amounts of variance than the quad- ratic function, though both were statistically significant). Due to the decrease in number and percentage of CD19+ cells, the absolute number of naϊve B cells is not significantly different in young and old (Fig. 1 D). The percentage of IgM memory B cells are not statistically different between young and old (Fig. 1 E, linear curve), but show an increase in old age compared to the middle aged group with the quadratic curve. The absolute number of IgM memory B cells decreased with age (Fig. 1 F). With age, switch memory B cells decreased in both percentage (Fig. 1 G) and absolute number (Fig. 1 H). The significant
decrease in switch memory B cells and the increase in percentage of naϊve and IgM memory B cells (from middle to old age) suggest an intrinsic defect in the ability of old B cells to undergo CSR. Therefore, we wanted to investigate whether CSR was decreased in CD19+ B cells stimulated in vitro with anti- CD40/IL-4, a stimulus leading to IgG production.
Aging down-regulates CSR in activated peripheral blood-derived human B cells B cells were stimulated in vitro with anti-CD40/IL-4. CSR was measured by γ1 circle transcripts (CTs). Briefly, CSR generates an extra-chromosomal reciprocal switch DNA recombination product, which includes the intronic heavy chain promoter 5' of the targeted CH gene, the DNA segment between Sμ and the targeted S region, and Cμ and is referred to as the CT (26). Fig. 2A and 2B show that these transcripts are reduced in B cells from elderly subjects. We have evidence that in the CD19+ B cell population, only IgM memory B cells switch in response to anti-CD40/IL-4 as shown below and as expected from other's results (27). Naϊve B cells require an additional B cell receptor (BCR) stimulus (anti-μ). We also looked at germline transcripts and found that they are present in B cells from young and elderly subjects at a similar extent, similar to that as we have seen in the murine system (9). Thus, our results indicating less CSR products suggest that the defect in aged B cells occurs at the CSR event and is not due to problems with accessibility, nor with the cytokine signaling pathway that leads to γ1 accessibility, as we have shown in murine B cells (9).
We also measured IgG production by ELISA of culture supernatants after 7 days stimulation with anti-CD40/IL-4. Fig. 2C shows that IgG levels in culture supernatants decrease with age and, as expected, parallel the data shown in Fig. 2B. Conversely, when we measured IgG levels in serum, we found them increased with age (Fig. 2D) as others have shown consistently (17, 28). We have done a few experiments with splenic B cells obtained from cadaveric donors (four subjects, aged 22-52) together with peripheral blood- derived B cells (six subjects, aged 22-53), and shown a similar pattern of IgG production in cultures of anti-CD40/IL-4-stimulated B cells (the 52 year old subject had about 14 of the IgG of the 22 year old subject as seen in the peri-
pheral blood-derived B cells, not shown). Therefore, our peripheral blood data are representative of peripheral B lymphocytes.
Aging down-regulates AID in activated peripheral blood-derived human B cells Because the reduction in CSR in old B cells could be due to reduced levels of AID, as- already shown in murine B cells (3, 9), we investigated the levels of AID transcripts in anti-CD40/IL-4-stimulated CD19+ B cells from subjects of different ages. Preliminary results indicated that stimulation with anti-CD40/IL-4, and to a lesser extent with IL-4, induced AID mRNA expression in peripheral blood-derived B cells from both young and elderly subjects. The level of AID expression was lower in old as compared with young B cells stimulated not only with anti-CD40/IL-4 (Fig. 3A), but also with IL-4. Human B cells require the activation of both CD40 and IL-4 signaling pathways to undergo optimal AID expression and likely Ig class switch (29). Fig. 3A shows that aging decreases AID mRNA expression in anti-CD407IL-4-stimulated CD19+ B cells from subjects of different ages, as determined by sqPCR and qPCR, respectively.
Aging down-regulates the E2A-encoded transcription factor E47 in activated peripheral blood-derived human B cells
To gain insight into the mechanisms underlying AID regulation, we analyzed the levels of expression of the E2/\-encoded transcription factor E47 in peripheral blood-derived B cells. Preliminary results determined optimal dose response and kinetics and indicated that stimulation with anti-CD40/IL-4, and to a lesser extent with anti-CD40 alone, induced E47 mRNA expression in peripheral blood-derived B cells from both young and elderly subjects. IL-4 alone was unable to induce E47 mRNA expression. Fig. 3B shows that aging decreases E47 mRNA expression in anti-CD40/IL-4-stimulated CD19+ B cells from subjects of different ages, as determined by qPCR. E47 and AID progressively and similarly decrease with age. The statistically significant correlation between E47 and AID is shown in Fig. 3C. Results show that as E47 increased, AID also increased (r = 0.80, significant at the 0.01 level, 2-tailed).
Higher E47 was also associated with higher CTs (r = 0.65, significant at the 0.01 level, 2-tailed, not shown). Likewise, there was a positive significant association between AID and CTs where greater AID was associated with greater CTs (r = 0.79, significant at the 0.01 level, 2-tailed, not shown).
Both memory and naive B cells show intrinsic defects in class switch with age
We have so far shown that CD19+ B cells lose their ability to undergo in vitro class switch with age and we have shown that there is an intrinsic defect in the expression of E47 and AID. The data shown herein do not clarify whether there is an intrinsic defect in the subsets of memory B cells or if the decrease we saw in class switch depends on the age-related reduction in the numbers of memory B cells. To clarify this point, we sorted naive and memory B cells which were then stimulated in vitro by anti-CD40/IL-4, a stimulus mainly for memory B cells. Sorted cells were also stimulated with anti-CD40/IL-4 and F(ab')2 fragments of anti-human IgM, used as surrogate antigen, because naϊve B cells require the activation of the B-cell receptor (BCR) signal transduction to undergo class switch (27). Fig. 4 shows that memory B cells express AID in response to anti-CD40/IL-4, independently from the presence of anti-lgM and differentiated into antibody-secreting cells. We conclude that the subset of memory B cells able to class switch in culture is likely the IgM memory population, although here we only looked at AID, and not also CT. As shown in Fig. 4, naϊve B cells do not express AID in response to anti-CD40/IL-4 and up-regulate AID only in the presence of BCR triggering by anti-lgM. Even under the best conditions of stimulation (anti-CD40/IL-4 and anti-lgM), the response of naϊve B cells was lower than that of memory B cells. Therefore, both IgM memory and naϊve B cells are negatively affected by aging. The old subject in pair #2 (Fig. 4B) is clearly exceptional from the other data in Figs. 3-4. We can conclude from these data on sorted subsets of B cells that the defect we observed in the ability of CD19+ cells to class switch upon in vitro stimulation with anti-CD40/IL- 4 does not simply depend on a reduction in the numbers of memory B cells but is an intrinsic defect of the switched cells (IgM memory in previous experiments
and naϊve and IgM memory here). The percentages naive, IgM memory, and switch memory B cells in the subjects of Fig. 4 are listed in Table I.
The order from left to right 1-4 corresponds to the # of the pair in the Figure. Phenotype (% cells) of old #2 is "young-like", (see text).
Both switch memory and IgM memory B cells have been shown to proliferate and differentiate into plasma cells in response to anti-CD40/IL-4 (27) but this differentiation would not be expected to increase AID at least in the switch memory cell population. We have shown this when naϊve, IgM memory, and switch memory B cells from young subjects were sorted and found that naϊve and IgM memory B cells had comparable levels of AID transcripts, whereas switch memory B cells had four-fold less as compared to the other subsets (Fig. 5). Thus, in unsorted populations, AID expression to anti-CD40/IL-4 is predominantly measuring the IgM memory cell population.
Significant differences in B cell functions were observed between young (18- 30) and old (>65) subjects
The younger age group (subjects from 18-30 years) differed from the older age group (aged greater than 65 years) when analyzed by independent samples f-test for percentage (%) and number (#) (Table II). The groups differed on every variable with the exceptions of the numbers of naϊve B cells and the percentage of IgM memory B cells, which is consistent with the findings above (Figs. 1 B and 1C).
Young: 18-30 years (12 subjects). Old: >65 years (15 subjects). Independent samples Mest were calculated.
The in vitro AID response of B cells to vaccination decreases with age as shown in Fig. 6. B cells (106 cells/ml), isolated using CD19 magnetic beads from the peripheral blood of subjects of different ages, before (filled circles) or after vaccination (open circles) with 1 μl of flu vaccine, were cultured with the indicated stimuli, for 7 days. At the end of this time, cells were harvested, RNA was extracted, and qPCR reactions were performed to evaluate AID normalized to GAPDH transcripts. Five μg of CpG was used to stimulate 1x106 B cells for the control in Fig. 6A.
Seven subjects (ages 22-71 years) were enrolled to evaluate the age- related effects of influenza vaccination on B cell Ig class switch. The blood from these subjects was drawn immediately before vaccination and 4-6 weeks after vaccination. Five tubes of heparinized blood and 1 tube for serum were drawn from each subject. Serum was used to evaluate by hemaglutination inhibition the response to vaccination to the whole vaccine as well as to the single antigens AG1 , AG2 and AG3. The single antigens included in the 2007-2008 (last year) influenza vaccine were: Flu antigen H1 N1 (A/Solomon lslands/3/2006- like), Flu antigen H3N2 (A/Wisconsin/67/2005), and Flu antigen B (B/Malaysia/ 2506/2004). One hundred μl of blood were used to evaluate by flow cytometry the following parameters: subsets of B cells (naϊve, IgM memory or switch memory B cells); expression of co-stimulatory molecules (CD40, CD80, CD86); and percent of regulatory T cells (CD4+CD25+ or CD8+CD28-). Cells were processed as follows. Briefly, B cells were isolated from the peripheral blood by- Ficoll gradient centrifugation using magnetic beads. Cells (1X106/ml) were stimulated in culture for 7 days with CpG (5 μg/ml), or with the single antigens. AG2 and AG3 (H3N2 and B) were already present in the 2006-2007 vaccine preparation. The antigens were used at the concentration of 1 μg/ml. At the end of the culture period, cells were harvested, and mRNA extracted to evaluate AID expression by real-time PCR. Results show that influenza vaccination induced up-regulation of AID mRNA expression in all subjects, and in response to all antigens, the up-regulation being higher in young than in old subjects. This up-regulation of AID was concomitant with up-regulation of the serum flu- specific IgG response against all antigens in Fig. 6. In human subjects, the serum hemaglutinin inactivation (HI) response to flu vaccination decreases with age in Fig. 7. Serum was collected from subjects of different ages, before (filled circles) or after vaccination (open circles) with 1 μl of flu vaccine, and analyzed by HI assay to evaluate antibody production to vaccine or to the single antigens present in the vaccine preparation. The HI assay is based on the ability of certain viruses or viral components to hemag- glutinate (HA) the red blood cells of specific animal species. Antibodies specific to influenza can inhibit agglutination. HI is useful for the measurement of anti-
body titers of sera. The assay is performed as follows. Sera from subjects un- immunized or flu-vaccinated were pre-treated with receptor destroying enzyme (Denke Seiken) for 20 h at 370C. To inactivate this enzyme, sera were then heated at 56°C for 60 min. Two-fold serial dilutions were done. Diluted serum (25 μl) was incubated with an equal volume of 4 HA units of whole vaccine or each of the HA antigen vaccine's components, for 1 h at room temperature and then 50 μl of a 1.25% suspension of human red blood cell, type O (HO)were added. Whole vaccine and HA antigen components were provided by Glaxo- SmithKline. After 2 h of incubation at room temperature, titers were determined. The results are expressed as reciprocal titer values. A four-fold rise in titer at two different time points pre- to post-vaccination indicates exposure to whole vaccine and to each of the HA antigens.
Figs. 6 and 7 show that AID gene expression is a good biomarker for predicting the effectiveness of flu vaccination. We have also compared gene expression levels by RT-PCR for three different categories of human subjects "at risk" for type 1 diabetes, with new onset of type 1 diabetes, or having long-term type 1 diabetes to healthy human subjects as a negative control. Both AID and IgH that has undergone class switching were measured for gene expression. RT-PCR was done using resting whole blood as the RNA source. No stimulation or culturing was required prior to analysis of gene expression.
For AID expression in Fig. 8, there was a significant difference between healthy controls and long-term patients. For gene expression of IgH that has undergone class switching in Fig. 9, there was a significant difference between healthy controls and long-term patients. Surprisingly, there was also a nearly significant difference (p = 0.0556) between new-onset and long-term patients.
Figs. 8 and 8 show that assaying for gene expression of biomarkers has utility outside of the context of vaccination. In vitro stimulation and culturing of B cells prior to analysis is not required.
Discussion
We show both quantitative and qualitative changes occurring in human B cells with aging. In particular, we confirm data from other groups showing that B-cell percentages and numbers decrease with age (17-19, 25), whereas the percentage of naive B cells increase with age (19, 25). Moreover, we show for the first time that the number of switch memory B cells decreases with age. Because of the decreased numbers of total B cells with age, the absolute number of switch memory B cells is extremely low in elderly subjects, whereas that of naive B cells is maintained. We also show, as others have reported (19), that IgM memory B cells are reduced in numbers, not in percentage. Therefore, the depletion in both switch memory and IgM memory B cells seems to be a feature of aging human B cells.
The significant decrease in the number of naive T cells and the shrinkage in their TCR repertoire reported in the elderly (30) can both account for the reduced stimulation of memory B cells at older ages in vivo, but likely does not account for the intrinsic B-cell defects seen here.
The decrease in switch memory B cells, the increase in the percentage of naive B cells and the absence of a decrease in the percentage of IgM memory B cells (or an actual increase in some subjects in IgM memory B cells, at least compared to middle age, see quadratic curve, Fig. 1 C) suggest an intrinsic defect in the ability of old B cells to undergo CSR. We have indeed shown in the present study that CSR induced in cultures of whole peripheral blood-derived B cells by anti-CD40/IL-4 is significantly impaired by aging. Our data on sorted subsets of B cells have shown that the defect we observed in the ability of CD19+ cells to class switch upon in vitro stimulation with anti- CD40/IL-4 is not simply depending on a reduction in the numbers of memory B cells (IgM memory/switch), but by an intrinsic defect in AID in both naive and (IgM) memory B cells. This leads to decreased amounts of IgG released in culture supernatants of B cells from old as compared to from the young or adults. But a seeming paradox exists: i.e., the ability of B cells to undergo class switch upon in vitro stimulation with anti-CD40/IL-4 is decreased, but there is a concomitant increase in serum IgG levels, as also others have shown (17, 28).
Both peripheral blood-derived B cells and splenic B cells are less able to produce IgG in response to anti-CD40/IL-4. These facts may be explained by the initial antigenic stimulation being defective in aged B cells. This is a major point of our studies. The accumulation in the sera of IgG, not from these types of cells, likely comes from plasmablasts (many in the bone marrow) (31 , 32) secreting immunoglobulin of suboptimal quality both in affinity and polyclonality (and autoimmune immunoglobulin (33)).
Studies of human VH6 and VK4 genes from peripheral blood-derived B cells have shown either a decrease or no change in SHM with age (34-38). In the human tonsil, diversity of the Ig repertoire is maintained with aging, although germinal center cells are reduced and naϊve cells are increased (21 ). These seemingly conflicting sets of results likely reflect the levels of chronic exposure to some environmental antigens that activate specific- or cross- reactive B cell clones. B cell clones that were stimulated initially in young subjects may show more SHM whereas those to a "new" antigen may be defective in age, as we suggest here.
We have previously shown in mice (8, 9) that the E2>A-encoded transcription factor E47 is down-regulated in old splenic activated B cells, leading to a reduction in the activation-induced cytidine deaminase (AID) and in CSR. This leads to reduced amounts of switched antibodies. Here we show that E47 is also reduced in human B cells and this leads to reduced AID, CTs and IgG released in culture supernatants. These are novel observations which help to establish the specific deficits in B-cell activity in aged humans and in particular provide molecular mechanisms for reduced Ig class switch seen in aged human subjects. E47 has been shown to be necessary for CSR (39-41 ) and SHM (39) as it transcriptionally regulates the gene for activation-induced cytidine deaminase (AID) (42). Therefore, E47 has a relevant role in all processes generating antibody diversity, such as V(D)J recombination (43-48), CSR and SHM. Our results herein clearly indicate that intrinsic defects in the B cell may have a crucial role in the generation of an effective humoral immune response in sensecence.
In conclusion, our results show an intrinsic defect in the ability of old B cells to undergo CSR. The transcription factor E47 in activated B cells is significantly impaired by aging. This leads to a reduction in AID and, in turn, to less switched antibodies produced by the activated B cells. Although there is a clear and significant decrease in both E47 and AID biomarkers with age, there is also an increase in the variability in the aged population for these two biomarkers (Figs. 3-4) which allows us to pinpoint important defects in the humoral immune response in elderly humans. The population of elderly people worldwide is increasing due to decreased mortality, but their morbidity has not decreased in parallel. Identification of the causes and impact of immunosenescence may offer the possibility for improving recovery from, preventing, or delaying some infectious diseases and improve the quality of life for our aging population.
References 1. Hodes, RJ. 1997. Aging and the immune system. Immunol Rev 160:5-8.
2. Weksler, M. E. 2000. Changes in the B-cell repertoire with age. Vaccine 18:1624-1628.
3. Frasca, D., R.L. Riley, and B. B. Blomberg. 2004. Effect of age on the immunoglobulin class switch. Crit Rev Immunol 24:297-320. 4. Eaton, S. M., E.M. Burns, K. Kusser, T.D. Randall, and L. Haynes. 2004.
Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med 200: 1613-1622.
5. Haynes, L., and S. M. Eaton. 2005. The effect of age on the cognate function of CD4+ T cells. Immunol Rev 205:220-228. 6. Pawelec, G., Y. Barnett, R. Forsey, D. Frasca, A. Globerson, J. McLeod,
C. Caruso, C. Franceschi, T. Fulop, S. Gupta, E. Mariani, E. Mocchegiani, and
R. Solana. 2002. T cells and aging, January 2002 update. Front Biosci
7:d1056-1183.
7. Yang, X., J. Stedra, and J. Cerny. 1996. Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. J Exp Med 183:959-970.
8. Frasca, D., E. Van der Put, A.M. Landin, D. Gong, R.L. Riley, and B. B. Blomberg. 2005. RNA stability of the E2A-encoded transcription factor E47 is lower in splenic activated B cells from aged mice. J Immunol 175:6633-6644.
9. Frasca, D., E. Van der Put, R.L. Riley, and B. B. Blomberg. 2004. Reduced Ig class switch in aged mice correlates with decreased E47 and activation-induced cytidine deaminase. J Immunol 172:2155-2162.
10. Casellas, R., A. Nussenzweig, R. Wuerffel, R. Pelanda, A. Reichlin, H. Suh, X. F. Qin, E. Besmer, A. Kenter, K. Rajewsky, and M. C. Nussenzweig. 1998. Ku80 is required for immunoglobulin isotype switching. Embo J 17:2404- 2411.
11. Honjo, T., K. Kinoshita, and M. Muramatsu. 2002. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol 20:165-196.
12. Kaminski, D.A., and J. Stavnezer. 2004. Antibody class switching: uncoupling S region accessibility from transcription. Trends Genet 20:337-340.
13. Manis, J. P., Y. Gu1 R. Lansfcrd, E. Sonoda, R. Ferrini, L. Davidson, K. Rajewsky, and F.W. Alt. 1998. Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. J Exp Med 187:2081-2089.
14. Petersen, S., R. Casellas, B. Reina-San-Martin, HT. Chen, M.J. Difilippantonio, P. C. Wilson, L. Hanitsch, A. Celeste, M. Muramatsu, D. R. Pilch, C. Redon, T. Ried, W. M. Bonner, T. Honjo, M. C. Nussenzweig, and A. Nussenzweig. 2001. AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. Nature 414:660-665.
15. Stavnezer, J. 2000. Immunology. A touch of antibody class. Science 288:984-985.
16. Lougaris, V., R. Badolato, S. Ferrari, and A. Plebani. 2005. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 203:48-66.
17. Franceschi, C, D. Monti, P. Sansoni, and A. Cossarizza. 1995. The immunology of exceptional individuals: the lesson of centenarians. Immunol
Today 16:12-16.
18. Wikby, A., B. Johansson, F. Ferguson, and J. Olsson. 1994. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol 29:531-541.
19. Shi, Y., T. Yamazaki, Y. Okubo, Y. Uehara, K. Sugane, and K. Agematsu. 2005. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 175:3262-3267.
20. Colonna-Romano, G., M. Bulati, A. Aquino, G. Scialabba, G. Candore, D. Lio, M. Motta, M. Malaguarnera, and C. Caruso. 2003. B cells in the aged: CD27, CD5, and CD40 expression. Mech Ageing Dev 124:389-393. 21. Kolar, G. R., D. Mehta, P.C. Wilson, and J. D. Capra. 2006. Diversity of the Ig repertoire is maintained with age in spite of reduced germinal centre cells in human tonsil lymphoid tissue. Scand J Immunol 64:314-324. 22. Cancro, M. P. 2005. B cells and aging: gauging the interplay of generative, selective, and homeostatic events. Immunol Rev 205:48-59. 23. Epeldegui, M., Y.P. Hung, A. McQuay, R.F. Ambinder, and O. Martinez- Maza. 2007. Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. MoI Immunol 44:934-942.
24. Tangye, S.G., and K.L. Good. 2007. Human lgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 179:13-19.
25. Chong, Y., H. Ikematsu, K. Yamaji, M. Nishimura, S. Nabeshima, S. Kashiwagi, and J. Hayashi. 2005. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances, lnt Immunol 17:383-390.
26. Litinskiy, M. B., B. Nardelli, D.M. Hubert, B. He, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3:822-829.
27. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells.
Science 298:2199-2202.
28. Paganelli, R., I. Quinti, U. Fagiolo, A. Cossarizza, C. Ortolani, E. Guerra, P. Sansoni, L. P. Pucillo, E. Scala, E. Cozzi, and et al. 1992. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. CHn Exp Immunol 90:351-354. 29. Zhou, C, A. Saxon, and K. Zhang. 2003. Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification. J Immunol 170: 1887-1893.
30. Pfister, G., D. Weiskopf, L. Lazuardi, R.D. Kovaiou, D.P. Cioca, M. Keller, B. Lorbeg, W. Parson, and B. Grubeck-Loebenstein. 2006. Naive T cells in the elderly: are they still there? Ann N Y Acad Sc/ 1067:152-157.
31. Radbruch, A., G. Muehlinghaus, E. O. Luger, A. Inamine, K.G. Smith, T. Dorner, and F. Hiepe. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741-750. 32. Manz, R.A., A. Thiel, and A. Radbruch. 1997. Lifetime of plasma cells in the bone marrow. Nature 388:133-134.
33. Hoyer, B. F., K. Moser, A.E. Hauser, A. Peddinghaus, C. Voigt, D. Eilat, A. Radbruch, F. Hiepe, and R.A. Manz. 2004. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199:1577-1584.
34. Banerjee, M., R. Mehr, A. Belelovsky, J. Spencer, and D. K. Dunn- Walters. 2002. Age- and tissue-specific differences in human germinal center B cell selection revealed by analysis of IgVH gene hypermutation and lineage trees. Eur J Immunol 32:1947-1957. 35. Chong, Y., H. Ikematsu, K. Yamaji, M. Nishimura, S. Kashiwagi, and J.
Hayashi. 2003. Age-related accumulation of Ig V(H) gene somatic mutations in peripheral B cells from aged humans. CHn Exp Immunol 133:59-66.
36. Rosner, K., D.B. Winter, C. Kasmer, G. L. Skovgaard, R.E. Tarone, V.A.
Bohr, and P.J. Gearhart. 2001. Impact of age on hypermutation of immunoglobulin variable genes in humans. J Clin Immunol 21 :102-115.
37. Troutaud, D., M. Drouet, C. Decourt, C. Le Morvan, and M. Cogne. 1999. Age-related alterations of somatic hypermutation and CDR3 lengths in human Vkappa4-expressing B lymphocytes. Immunology 97:197-203.
38. van Dijk-Hard, I., I. Soderstrom, S. FeId1 D. Holmberg, and I. Lundkvist. 1997. Age-related impaired affinity maturation and differential D-JH gene usage in human VH6-expressing B lymphocytes from healthy individuals. Eur J Immunol 27:1381-1386.
39. Michael, N., H. M. Shen, S. Longerich, N. Kim, A. Longacre, and U. Storb. 2003. The E box motif CAGGTG enhances somatic hypermutation without enhancing transcription. Immunity 19:235-242.
40. Quong, M.W., DP. Harris, S. L. Swain, and C. Murre. 1999. E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination. Embo J 18:6307-6318.
41. Sugai, M., H. Gonda, T. Kusunoki, T. Katakai, Y. Yokota, and A. Shimizu. 2003. Essential role of Id2 in negative regulation of IgE class switching. Nat Immunol 4:25-30.
42. Sayegh, CE. , M.W. Quong, Y. Agata, and C. Murre. 2003. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat Immunol 4:586-593. 43. Bain, G., E. C. Robanus Maandag, H. P. te Riele, AJ. Feeney, A.
Sheehy, M. Schlissel, S.A. Shinton, R.R. Hardy, and C. Murre. 1997. Both E12 and E47 allow commitment to the B cell lineage. Immunity 6:145-154.
44. Goebel, P., N. Janney, J. R. Valenzuela, W.J. Romanow, C. Murre, and AJ. Feeney. 2001. Localized gene-specific induction of accessibility to V(D)J recombination induced by E2A and early B cell factor in nonlymphoid cells. J Exp Med 194:645-656.
45. Kee, B. L., G. Bain, and C. Murre. 2002. IL-7Ralpha and E47: independent pathways required for development of multipotent lymphoid progenitors. Embo J 21 :103-113. 46. Kee, B. L., and C. Murre. 1998. Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12. J Exp Med 188:699-713.
47. Romanow, W.J., A.W. Langerak, P. Goebel, I. L. Wolvers-Tettero, J.J. van Dongen, A.J. Feeney, and C. Murre. 2000. E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells. MoI Cell 5:343-353. 48. Sigvardsson, M., M. O'Riordan, and R. Grosschedl. 1997. EBF and E47 collaborate to induce expression of the endogenous immunoglobulin surrogate light chain genes. Immunity 7:25-36.
Patents, patent applications, books, and other publications cited herein are incorporated by reference in their entirety. In stating a numerical range, it should be understood that all values within the range are also described (e.g., one to ten also includes every integer value between one and ten as well as all intermediate ranges such as two to ten, one to five, and three to eight). The term "about" may refer to the statistical uncertainty associated with a measurement or the variability in a numerical quantity which a person skilled in the art would understand does not affect operation of the invention or its patentability.
All modifications and substitutions that come within the meaning of the claims and the range of their legal equivalents are to be embraced within their scope. A claim reciting "comprising" allows the inclusion of other elements to be within the scope of the claim; the invention is also described by such claims reciting the transitional phrases "consisting essentially of (i.e., allowing the inclusion of other elements to be within the scope of the claim if they do not materially affect operation of the invention) or "consisting of (i.e., allowing only the elements listed in the claim other than impurities or inconsequential activi- ties which are ordinarily associated with the invention) instead of reciting the "comprising" term. Any of these three transitions can be used to claim the invention.
It should be understood that an element described in this specification should not be construed as a limitation of the claimed invention unless it is explicitly recited in the claims. Thus, the granted claims are the basis for determining the scope of legal protection instead of a limitation from the specification which is read into the claims. In contradistinction, the prior art is explicitly exclu-
ded from the invention to the extent of specific embodiments that would anticipate the claimed invention or destroy novelty.
Moreover, no particular relationship between or among limitations of a claim is intended unless such relationship is explicitly recited in the claim (e.g., the arrangement of components in a product claim or order of steps in a method claim is not a limitation of the claim unless explicitly stated to be so). All possible combinations and permutations of individual elements disclosed herein are considered to be aspects of the invention. Similarly, generalizations of the invention's description are considered to be part of the invention. From the foregoing, it would be apparent to a person of skill in this art that the invention can be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments should be considered only as illustrative, not restrictive, because the scope of the legal protection provided for the invention will be indicated by the appended claims rather than by this specification.
Claims
1. A method of predicting or determining a B-cell defect in a humoral immune response of a human subject, said method comprising:
(a) obtaining a biological sample containing B cells from the human subject and
(b) detecting expression of transcription factor E47, activation-induced cytidine deaminase (AID), or both in the B cells; wherein reduced expression of E47, AID, or both as compared to a control indicates that there is a B-cell defect in the humoral immune response.
2. A method of predicting or determining a B-cell defect in a humoral immune response of a human subject, said method comprising:
(a) obtaining a biological sample containing B cells from the human subject and
(b) detecting expression of transcription factor E47, activation-induced cytidine deaminase (AID), immunoglobulin heavy chain (IgH) that has undergone class switching, or a combination thereof in the B cells; wherein reduced expression of E47, AID, IgH or a combination thereof as compared to a control indicates that there is a B-cell defect in the humoral immune response.
3. The method according to Claim 1 or 2, wherein said human subject is more than 65 years of age.
4. The method according to Claim 1 or 2, wherein said human subject has type 1 diabetes or is at an early stage of disease.
5. The method according to any one of Claims 1 to 4 further comprising culturing in vitro B cells contained in said biological sample.
6. The method according to any one of Claims 1 to 5 further comprising stimulating the B cells before detecting expression therein.
7. The method according to Claim 6, wherein B cells are stimulated with at least an antibody specific for a B-cell receptor, a ligand for the B-cell receptor, a cytokine, or a combination thereof.
8. The method according to any one of Claims 1 to 6 further comprising isolating B cells from said biological sample before detecting expression therein.
9. The method according to Claim 8, wherein CD19-expressing B cells are isolated.
10. The method according to any one of Claims 2 to 9, wherein class switching of antibody produced by B cells is detected.
11. The method according to any one of Claims 2 to 10, wherein somatic mutation of antibody produced by B cell is detected.
12. The method according to any one of Claims 1 to 11 , wherein said human subject was or will be immunized with one or more vaccines on the same day or within one week of obtaining the biological sample.
13. The method according to Claim 12, wherein at least one of said vaccines is selected from the group consisting of diphtheria, influenza, measles, meningococcal, mumps, pertussis, pneumococcal, rubella, tetanus, varicella, zoster, and cancer vaccines.
14. The method according to Claim 12, wherein at least one of said vaccines comprises a carbohydrate antigen which induces a humoral immune response against a pathogen.
15. The method according to Claim 12, wherein at least one of said vaccines comprises a proteinaceous antigen which induces a humoral immune response against a pathogen.
16. The method according to Claim 12, wherein at least one of said vaccines comprises an antigen of the human subject.
17. A method of immunizing a human subject having B-cell defects in a humoral immune response, said method comprising: administering an increased dose of vaccine to the human subject as compared to human subjects who do not have the B-cell defect, administering an adjuvant with a vaccine to the human subject, or administering both the adjuvant and the increased dose of vaccine to the human subject.
18. Use of a vaccine for immunizing a human subject having B-cell defects in a humoral immune response, wherein an increased dose of the vaccine is administered to the human subject as compared to a control, an adjuvant with the vaccine is administered to the human subject, or both the adjuvant and the increased dose of vaccine is administered to the human subject.
19. Use of an antigen and/or an adjuvant for manufacture of a vaccine used for immunization of a human subject having B-cell defects in a humoral immune response, wherein an increased amount of antigen is included in the vaccine as compared to vaccine administered to human subjects who do not have the B- cell defect, an adjuvant is included in the vaccine which is not required when vaccine is administered to human subjects who do not have the B-cell defect, or both the adjuvant and the increased dose are included in the vaccine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3079408P | 2008-02-22 | 2008-02-22 | |
US61/030,794 | 2008-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009105275A2 true WO2009105275A2 (en) | 2009-08-27 |
WO2009105275A3 WO2009105275A3 (en) | 2009-12-03 |
Family
ID=40986116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/001131 WO2009105275A2 (en) | 2008-02-22 | 2009-02-23 | Human biomarkers for determining intrinsic b-cell defects |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009105275A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160194382A1 (en) * | 2009-07-15 | 2016-07-07 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
-
2009
- 2009-02-23 WO PCT/US2009/001131 patent/WO2009105275A2/en active Application Filing
Non-Patent Citations (5)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160194382A1 (en) * | 2009-07-15 | 2016-07-07 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
US10344076B2 (en) * | 2009-07-15 | 2019-07-09 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
Also Published As
Publication number | Publication date |
---|---|
WO2009105275A3 (en) | 2009-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ryan et al. | Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection | |
Suan et al. | CCR6 defines memory B cell precursors in mouse and human germinal centers, revealing light-zone location and predominant low antigen affinity | |
Frasca et al. | Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells | |
van de Veen et al. | IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses | |
Hoh et al. | Single B-cell deconvolution of peanut-specific antibody responses in allergic patients | |
Sharfe et al. | The effects of RelB deficiency on lymphocyte development and function | |
Ghia et al. | Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 | |
Wei et al. | Hypomethylation of the IL17RC promoter associates with age-related macular degeneration | |
Majewska et al. | Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis | |
Kared et al. | Adaptive NKG2C+ CD57+ natural killer cell and Tim-3 expression during viral infections | |
Zhuang et al. | Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus | |
Fleischer et al. | Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus | |
Braun et al. | Porcine B cell subset responses to toll-like receptor ligands | |
Liu et al. | IL-2 and autocrine IL-4 drive the in vivo development of antigen-specific Th2 T cells elicited by nematode parasites | |
Wang et al. | Reduced levels of cytosolic DNA sensor AIM2 are associated with impaired cytokine responses in healthy elderly | |
Goenka et al. | Memory B cells form in aged mice despite impaired affinity maturation and germinal center kinetics | |
Arsenović-Ranin et al. | Influence of aging on germinal centre reaction and antibody response to inactivated influenza virus antigens in mice: sex-based differences | |
Chen et al. | Development of allergen-specific IgE in a food-allergy model requires precisely timed B cell stimulation and is inhibited by Fgl2 | |
US20220091111A1 (en) | Methods and compositions for diagnosing neurodegenerative disease | |
JP2018025554A (en) | Inflammatory disease marker | |
Janssen et al. | Responses of dendritic cells to TLR-4 stimulation are maintained in the elderly and resist the effects of CMV infection seen in the young | |
Nehete et al. | Age-and sex-associated differences in phenotypic and functional characteristics of peripheral blood lymphocytes in chimpanzees (Pan troglodytes) | |
Garner-Spitzer et al. | Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees | |
Sen et al. | Aberration of CCR7+ CD8+ memory T cells from patients with systemic lupus erythematosus: an inducer of T helper type 2 bias of CD4+ T cells | |
WO2009105275A2 (en) | Human biomarkers for determining intrinsic b-cell defects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09712180 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09712180 Country of ref document: EP Kind code of ref document: A2 |